{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.08928"}, {"@name": "filename", "#text": "13820_001063573.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "4\u00ed\nUFRGS\nUNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL\nUniversidade Federal do Rio Grande do Sul\nFaculdade de Medicina\nPrograma de P\u00f3s-Gradua\u00e7\u00e3o: Ci\u00eancias em Gastroenterologia e Hepatologia\nDisserta\u00e7\u00e3o de Mestrado\nPREVAL\u00caNCIA E FATORES ASSOCIADOS \u00c0 CONSTIPA\u00c7\u00c3O INTESTINAL EM\nPACIENTES EM HEMODI\u00c1LISE\nAutor: Etielle Pereira Sonaglio\nOrientador: Prof. Dr. Fernando Herz Wolff\nEtielle Pereira Sonaglio\nPREVAL\u00caNCIA E FATORES ASSOCIADOS \u00c0 CONSTIPA\u00c7\u00c3O INTESTINAL EM\nPACIENTES EM HEMODI\u00c1LISE\nDisserta\u00e7\u00e3o apresentada ao Programa de P\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias em Gastroenterologia e Hepatologia da Universidade Federal do Rio Grande do Sul, como requisito parcial para obten\u00e7\u00e3o do t\u00edtulo de Mestre em Gastroenterologia e Hepatologia.\nOrientador: Prof. Dr. Fernando Herz Wolff\nCIP CATALOGA\u00c7\u00c3O NA PUBLICA\u00c7\u00c3O\nCIP - Cataloga\u00e7\u00e3o na Publica\u00e7\u00e3o\nPereira Sonaglio , Etielle\nPREVAL\u00caNCIA E FATORES ASSOCIADOS \u00c0 CONSTIPA\u00c7\u00c3O INTESTINAL EM PACIENTES EM HEMODI\u00c1LISE / Etielle Pereira Sonaglio . \u2014 2010.\n00 f..\nOrientador: Fernando Herz Wolff.\nDisserta\u00e7\u00e3o (Mestrado) \u2014 Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Programa de P\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias em Gastroenterologia e Hepatologia, Porto Alegre, BR-RS, 2018.\n1. Constipa\u00e7\u00e3o. 2. Doen\u00e7a Renal Cr\u00f4nica. 3. Hemodi\u00e1lise. 4. Preval\u00eancia . I. Herz Wolff, Fernando, orient. II. Titulo.\nElaborada peto Sistema de Gera\u00e7\u00e3o Autom\u00e1tica de Ftoha Catatogr\u00e2fica da UFRGS com os dados fornecidos pelo(a) autor(a).\nDEDICAT\u00d3RIA\nAos profissionais da \u00e1rea de nefrologia, t\u00e3o dedicados ao trabalho di\u00e1rio de minimizar os efeitos da Doen\u00e7a Renal Cr\u00f4nica na vida dos pacientes. Em especial, \u00e0 equipe do Centro de Nefrologia do Hospital Moinhos de Vento.\nA todos os pesquisadores, que n\u00e3o medem esfor\u00e7os para e elucida\u00e7\u00e3o de possibilidades terap\u00eauticas aos portadores de doen\u00e7as cr\u00f4nicas, mesmo em face das dificuldades as quais as pesquisas s\u00e3o afetadas.\nAos pacientes em hemodi\u00e1lise que, diariamente, lutam pelas suas vidas de uma maneira surpreendente, nos fazendo repensar nas nossas!\nE a todas as pessoas que direta ou indiretamente me apoiaram nessa conquista.\n\u201cLeve na sua mem\u00f3ria para o resto de sua vida as coisas boas que surgiram no meio das dificuldades. Elas ser\u00e3o uma prova de sua capacidade em vencer as provas, e lhe dar\u00e3o confian\u00e7a na presen\u00e7a divina, que nos auxilia em qualquer situa\u00e7\u00e3o, em qualquer tempo, e diante de qualquer obst\u00e1culo\u201d Chico Xavier\nAGRADECIMENTOS\nAos meus pais, \u00c2ngela e Nelson, agrade\u00e7o por todo amor e \u00e0 minha educa\u00e7\u00e3o. Tudo que sou hoje, pessoal e profissionalmente, devo a voc\u00eas. Obrigada pela for\u00e7a e aten\u00e7\u00e3o em todos os passos que j\u00e1 percorri. Obrigada pelo incentivo e motiva\u00e7\u00e3o com os quais voc\u00eas impulsionam meus caminhos.\nAos meus irm\u00e3os, Luciano, Andr\u00e9, Thamires, Carlos e Luiz, agradec\u00e7o pela cumplicidade e incentivo. Obrigada por serem meus melhores elos entre o meu passado, presente e futuro.\nAo Rodrigo, agrade\u00e7o por todo carinho e companheirismo, por compreender quando n\u00e3o pude estar presente e por estar sempre disposto a me ajudar, com todo amor e aten\u00e7\u00e3o.\nAo meu orientador, Prof Dr Fernando Wolff, agrade\u00e7o pelo acolhimento, ensinamentos, disponibilidade e aten\u00e7\u00e3o surpreendentes. Agrade\u00e7o especialmente a sua paci\u00eancia com minhas inquieta\u00e7\u00f5es. Agradecimentos tamb\u00e9m estendidos a sua linda fam\u00edlia.\nAs minhas colegas e amigas Amanda e Rafaela Lienert com contribui\u00e7\u00f5es extremamente importantes para o meu trabalho, desde o princ\u00edpio at\u00e9 o fim.\nA Rosmeri Lazzaretti, pelo incentivo para plena realiza\u00e7\u00e3o de minhas atividades, me apoiando e incentivando a desenvolver um trabalho relevante e a ser uma profissional forte.\nAo Centro de Di\u00e1lise do Hospital Moinhos de Vento, na pessoa de seu coordenador Dr. Renato Eick, e a todos os demais m\u00e9dicos, residentes, enfermeiros, psic\u00f3logos e t\u00e9cnicos, que reconheciam no meu estudo uma investiga\u00e7\u00e3o promissora para qualidade de vida dos pacientes em hemodi\u00e1lise, e contribu\u00edram com seu conhecimento e disponibilidade para a realiza\u00e7\u00e3o deste trabalho.\nSUM\u00c1RIO\nRESUMO...........................................................07\nABSTRACT.........................................................09\nAPRESENTA\u00c7\u00c3O.....................................................11\nLISTA DE ABREVIATURAS............................................12\nLISTA DE TABELAS.................................................14\nLISTA DE QUADROS.................................................15\nLISTA DE FIGURAS.................................................16\nINTRODU\u00c7\u00c3O.......................................................17\nREVIS\u00c3O BIBLIOGR\u00c1FICA............................................20\nDoen\u00e7a Renal Cr\u00f4nica........................................20\nEtiologia e Epidemiologia da DRC............................23\nHemodi\u00e1lise.................................................24\nConstipa\u00e7\u00e3o Instestinal.....................................25\nTratamento da Constipa\u00e7\u00e3o Intestinal........................30\nJUSTIFICATIVA....................................................38\nQUEST\u00c3O DE PESQUISA..............................................39\nHIP\u00d3TESE.........................................................40\nOBJETIVOS........................................................41\nARTIGO...........................................................42\nTabelas Do Artigo...........................................58\nRefer\u00eancias- Artigo.........................................63\nCONCLUS\u00d5ES...............................................69\nPERSPETIVAS..............................................70\nCONSIDERA\u00c7\u00d5ES FINAIS.....................................71\nREFER\u00caNCIAS DISSERTA\u00c7\u00c3O..................................72\nAP\u00caNDICE I - TERMO DE CONSCENTIMENTO LIVRE E ESCLARECIDO..91\nAP\u00caNDICE II - INSTRUMENTO DE COLETA DE DADOS.............93\nANEXO I - CRIT\u00c9RIOS PARA CONSTIPA\u00c7\u00c3O - ROMA III..........95\nANEXO II- ESCALA DE BRISTOL..............................97\nANEXO III - REGISTRO ALIMENTAR...........................98\nRESUMO\nAltera\u00e7\u00f5es gastrointestinais em pacientes com doen\u00e7a renal cr\u00f4nica s\u00e3o queixas comuns, sendo a constipa\u00e7\u00e3o considerada um dos sintomas mais prevalentes. O tratamento deste sintoma \u00e9 limitado nesta popula\u00e7\u00e3o, devido \u00e0s modifica\u00e7\u00f5es diet\u00e9ticas impostas pela perda da fun\u00e7\u00e3o renal e m\u00e9todos dial\u00edticos, especialmente na hemodi\u00e1lise. Dados locais sobre a preval\u00eancia e fatores associados \u00e0 constipa\u00e7\u00e3o s\u00e3o pouco conhecidos em nosso meio. Neste estudo transversal, foram inclu\u00eddos 57 participantes que realizam hemodi\u00e1lise h\u00e1 pelo menos 3 meses no Hospital Moinhos de Vento em Porto Alegre, Brasil. Um question\u00e1rio foi utilizado para avaliar dados sociodemogr\u00e1ficos e cl\u00ednicos potencialmente associados \u00e0 constipa\u00e7\u00e3o, a qual foi definida utilizando os crit\u00e9rios de ROMA III. Foi diagnosticada constipa\u00e7\u00e3o em 28 pacientes nesta amostra (49,1%). Do total da amostra, 34 indiv\u00edduos (59,6%) relataram estar utilizando ou j\u00e1 terem utilizado laxantes em algum momento. Entre os constipados, 23 (82%) relataram esse uso. Outros 11 indiv\u00edduos usam laxativos cronicamente, ainda que n\u00e3o tenham sido classificados como constipados pelos crit\u00e9rios de ROMA III. Considerando a autopercep\u00e7\u00e3o, relataram \u201cdificuldade para evacuar\u201d 21/57 (36,8%). A concord\u00e2ncia entre a autopercep\u00e7\u00e3o de \u201cdificuldade para evacuar\u201d e constipa\u00e7\u00e3o pelos crit\u00e9rios de ROMA III ocorreu em 34 (59,6%) dos indiv\u00edduos. Entre os 28 pacientes constipados, 17 (77,3%) referem que sintomas gastrointestinais interferem no seu bem-estar, enquanto que entre os 29 pacientes n\u00e3o constipados, somente 5 (22,7%) referem esta interfer\u00eancia (p = 0,01). Quando investigado os fatores potencialmente associados \u00e0 constipa\u00e7\u00e3o,a inatividade f\u00edsica (Raz\u00e3o de preval\u00eancia 53,4; Teste exato de Fisher p = 0,052) e o sexo feminino (Raz\u00e3o de Preval\u00eancia 1,6; Pearson X p = 0,07) apresentaram tend\u00eancia\u00e0 associa\u00e7\u00e3o significativa. No entanto, n\u00e3o foi encontrada associa\u00e7\u00e3o significativa entre constipa\u00e7\u00e3o e escolaridade, faixa et\u00e1ria, utiliza\u00e7\u00e3o de carbonato de c\u00e1lcio, presen\u00e7a de\ndiabetes, estado nutricional e consumo de fibras atual. Conclus\u00f5es: A constipa\u00e7\u00e3o intestinal \u00e9 um sintoma frequente em pacientes em hemodi\u00e1lise no nosso meio. A utiliza\u00e7\u00e3o dos crit\u00e9rios de ROMA III para o diagn\u00f3stico de constipa\u00e7\u00e3o permite diagnosticar um maior n\u00famero de casos quando comparado apenas \u00e0 autopercep\u00e7\u00e3o. A maior parte dos pacientes da amostra faz ou j\u00e1 fez uso cr\u00f4nico de laxantes, ainda que boa parte destes n\u00e3o se considere constipado, ou seja, classificados como constipados pelos crit\u00e9rios de ROMA III. Considerando-se a alta preval\u00eancia e interfer\u00eancia no bem-estar, a abordagem sobre a presen\u00e7a de constipa\u00e7\u00e3o deve ser rotineira nessa popula\u00e7\u00e3o, a fim de alcan\u00e7ar-se um diagn\u00f3stico e manejo corretos.\nPalavras-Chave: Constipa\u00e7\u00e3o; Doen\u00e7a Renal Cr\u00f4nica; Insufici\u00eancia Renal Cr\u00f4nica; Hemodi\u00e1lise; Preval\u00eancia\nABSTRACT\nGastrointestinal problems are common complaints in patients with chronic kidney disease and constipation is considered one of the most prevalent symptoms. Treatment options for this symptom are limited in this population because of the dietary restrictions imposed by loss of renal function and by dialysis methods, especially hemodialysis. There are few local data on the prevalence of factors associated with constipation in our country. In this cross-sectional study, 57 patients who had been receiving hemodialysis treatment at the Hospital Moinhos de Vento, in Porto Alegre, Brazil, for least 3 months were studied. A questionnaire was used to collect sociodemographic and clinical data potentially associated with constipation, which was defined using the ROMA III criteria. Constipation was diagnosed in 28 patients in the sample (49.1%). In the whole sample, 34 people (59.6%) reported they were using or had previously used laxatives at some point. Twenty-three (82%) of those with constipation reported using laxatives. Another 11 were on chronic laxatives, but were not classified as constipated using the ROMA III criteria. On the basis of own perception, 21/57 (36.8%) reported \u201cdifficulty evacuating\u201d. Agreement between patients' own perceptions of \u201cdifficulty evacuating\u201d and constipation according to the ROMA III criteria was observed in 34 (59.6%) of the participants. Seventeen (77.3%) of the 28 constipated patients reported that their gastrointestinal symptoms interfered with their wellbeing, whereas just 5 (22.7%) of the 29 patients without constipation reported the same interference (p = 0.01). Investigation of factors potentially associated with constipation detected that inactivity (Prevalence ratio 53.4; Fisher's exact test p = 0.052) and female sex (Prevalence ratio 1.6; PearsonA p = 0.07) exhibited tendencies towards a significant association. However, there were no significant associations between constipation and educational level, age group, use of calcium carbonate, presence of diabetes, nutritional status, or current fiber consumption.\nConclusions: Constipation is a common symptom among patients on hemodialysis in our country. Use of the ROMA III criteria diagnoses a higher number of cases of constipation than patients' own perception alone. The majority of patients in the sample have used or were still using laxatives chronically, even though a considerable proportion of these patients were not considered constipated,they were not classified as constipated according to the ROMA III criteria. Considering its high prevalence and its impact on wellbeing, whether patients have constipation should be routinely investigated in this population, to enable correct diagnosis and management.\nKeywords: Constipation; Chronic kidney disease; Chronic renal failure; Hemodialysis; Prevalence\nAPRESENTA\u00c7\u00c3O\nEtielle Pereira Sonaglio, nutricionista, formada pelo Centro Universit\u00e1rio Franciscano (UNIFRA) em Santa Maria-RS (2009). Realizou p\u00f3s-gradua\u00e7\u00e3o Latu Sensu em Nutri\u00e7\u00e3o em Oncologia (2011) e em Pesquisa Cl\u00ednica (2015) pelo Instituto de Educa\u00e7\u00e3o e Pesquisa do Hospital Moinhos de Vento-Porto Alegre (IEP-HMV). Completou os cr\u00e9ditos necess\u00e1rios para defesa da disserta\u00e7\u00e3o de mestrado no Programa de P\u00f3s-Gradua\u00e7\u00e3o: Ci\u00eancias em Gastroenterologia e Hepatologia da Universidade Federal do Rio Grande do Sul.\nLISTA DE ABREVIATURAS\nIEP-HMV: Instituto de Educa\u00e7\u00e3o e Pesquisa do Hospital Moinhos de Vento\nUNIFRA: Centro Universit\u00e1rio Franciscano\nDRC: Doen\u00e7a Renal Cr\u00f4nica\nTRS: Terapia Renal Substitutiva\nHD: Hemodi\u00e1lise\nDP: Di\u00e1lise Peritoneal\nTR: Transplante Renal\nDM: Diabetes Mellitus\nHAS: Hipertens\u00e3o Arterial Sist\u00eamica\nSGI: Sintomas Gastrointestinais\nCI: Constipa\u00e7\u00e3o Intestinal\nTFG: Taxa de Filtra\u00e7\u00e3o glomerular\nNKF: National Kidney Foundation\nKDOQI: Kidney Disease Outcome Quality Initiative\nCI: Constipa\u00e7\u00e3o Intestinal\nTGI: Trato Gastrointestinal\nEUA: Estados Unidos da Am\u00e9rica\nWGO: World Gastroenterology Organisation\nMI: Microbiota intestinal\nIMC: \u00cdndice de Massa Corporal\nKg: Kilograma\nKg/m2: Kilograma por metro quadrado\nm: Metros\nSPSS: Statistical Package for Social Sciences\nANOVA: An\u00e1lise de vari\u00e2ncia\nOR: Odds Ratio\nIC: Intervalo de Confian\u00e7a\nLISTA DE TABELAS\nTabela 1. Caracter\u00edsticas da amostra (n = 57)\nTabela 2: Preval\u00eancia de constipa\u00e7\u00e3o e caracter\u00edstica das fezes (N = 57)\nTabela 3: Fatores associados \u00e0 constipa\u00e7\u00e3o em pacientes em hemodi\u00e1lise (N = 57)\nTabela 4: Preval\u00eancia de sintomas gastrointestinais auto referidos (N=57)\nTabela 5: Composi\u00e7\u00e3o nutricional da dieta em pacientes em hemodi\u00e1lise conforme registro\nalimentar de 2 dias (N = 26)\nLISTA DE QUADROS\nQuadro 1. Estadiamento da doen\u00e7a renal cr\u00f4nica proposto pelo KDOQI\nQuadro 2: Estadiamento da doen\u00e7a renal cr\u00f4nica proposto pelo Minist\u00e9rio da Sa\u00fade\nLISTA DE FIGURAS\nFigura 1. Escala de Bristol\n1.\tINTRODU\u00c7\u00c3O\nA Doen\u00e7a Renal Cr\u00f4nica (DRC) consiste na perda progressiva e, geralmente, irrevers\u00edvel das fun\u00e7\u00f5es renais glomerulares, tubulares e end\u00f3crinas , , . V\u00e1rias podem ser as causas da DRC, sendo as mais frequentes as complica\u00e7\u00f5es do Diabetes Melitus (DM) e da Hipertens\u00e3o Arterial Sist\u00eamica (HAS)4,5,6. Em fase terminal da doen\u00e7a, \u00e9 necess\u00e1ria a introdu\u00e7\u00e3o de Terapia Renal Substitutiva (TRS), a qual pode ser: hemodi\u00e1lise, di\u00e1lise peritoneal ou transplante renal . Nas \u00faltimas d\u00e9cadas, a DRC tem sido diagnosticada de forma crescente em todo mundo8,9,10.\nIndiv\u00edduos com DRC em fase terminal, especialmente quando em TRS, apresentam desequil\u00edbrio metab\u00f3lico e hidroeletrol\u00edtico que impacta no funcionamento de outros \u00f3rg\u00e3os e sistemas, incluindo o sistema gastrointestinal , . Sintomas Gastrointestinais (SGI), como dor abdominal, diarreia, n\u00e1useas e constipa\u00e7\u00e3o, s\u00e3o descritos em at\u00e9 70% dos pacientes em TRS13,14,15.\nDentre os SGI a constipa\u00e7\u00e3o intestinal (CI) \u00e9 uma das queixas mais frequentes16,17,18. Dados da literatura sugerem uma preval\u00eancia que varia de 14,2% a 71,7% deste sintoma em pacientes em alguma forma de TRS , , , , , , , .\nAinda que a constipa\u00e7\u00e3o intestinal n\u00e3o esteja diretamente relacionada a complica\u00e7\u00f5es graves ou mortalidade, est\u00e1 associada a um impacto negativo na qualidade de vida, tanto em indiv\u00edduos saud\u00e1veis, quanto em indiv\u00edduos em hemodi\u00e1lise24,25,26. Entre as manifesta\u00e7\u00f5es associadas \u00e0 constipa\u00e7\u00e3o est\u00e3o o desconforto abdominal, dificuldade ou dor ao evacuar, sangramento anal, forma\u00e7\u00e3o de fecaloma, obstru\u00e7\u00e3o intestinal e doen\u00e7a hemorroid\u00e1ria 27,28\nA elevada preval\u00eancia de constipa\u00e7\u00e3o relatada nesta popula\u00e7\u00e3o, al\u00e9m dos aspectos metab\u00f3licos, pode ser justificada por fatores que acometem a vida do paciente em TRS, tais como o sedentarismo, as restri\u00e7\u00f5es diet\u00e9ticas de minerais e de l\u00edquidos, al\u00e9m da utiliza\u00e7\u00e3o de medica\u00e7\u00f5es de uso cont\u00ednuo, especialmente os quelantes de f\u00f3sforo a base de c\u00e1lcio,\nlargamente utilizados nesta popula\u00e7\u00e3o para redu\u00e7\u00e3o dos n\u00edveis de f\u00f3sforo na circula\u00e7\u00e3o\n,\t19,20,29,30\nsangu\u00ednea ,\t.\nEmbora n\u00e3o exista uma recomenda\u00e7\u00e3o diet\u00e9tica espec\u00edfica para o manejo da constipa\u00e7\u00e3o intestinal funcional na popula\u00e7\u00e3o em di\u00e1lise, as diretrizes da Organiza\u00e7\u00e3o Mundial de Gastroenterologia (2013) sugerem, para individuos saud\u00e1veis, que o tratamento de primeira linha deva ser baseado em modifica\u00e7\u00f5es comportamentais, que incluem aumento na ingest\u00e3o de fibras (em m\u00e9dia 25g/dia), adequa\u00e7\u00e3o da ingest\u00e3o h\u00eddrica (1.5-2.0 l/dia) e atividade f\u00edsica regular.\nPor\u00e9m, essas pr\u00e1ticas t\u00eam aplicabilidade limitada nos pacientes em hemodi\u00e1lise devido \u00e0s restri\u00e7\u00f5es j\u00e1 mencionadas. Sendo assim, o que se observa na literatura \u00e9 que o consumo de fibras por via alimentar nesta popula\u00e7\u00e3o \u00e9 menor quando comparada a popula\u00e7\u00f5es saud\u00e1veis, possivelmente ligada ao fato dos vegetais, frutas, e gr\u00e3o integrais, serem as maiores fontes de pot\u00e1ssio, mineral que deve ser consumido com cautela por essa popula\u00e7\u00e3o , , . A restri\u00e7\u00e3o h\u00eddrica \u00e9 praticamente uma recomenda\u00e7\u00e3o universal nos pacientes em hemodi\u00e1lise pelas altera\u00e7\u00f5es na elimina\u00e7\u00e3o, com objetivo de evitar a hipervolemia . J\u00e1 a atividade f\u00edsica \u00e9, em muitos casos, limitada pelas comorbidades e condi\u00e7\u00e3o geral dos pacientes34.\nObserva-se, na pr\u00e1tica cl\u00ednica, que o m\u00e9todo mais utilizado para amenizar o sintoma de CI em pacientes com DRC em hemodi\u00e1lise \u00e9 o uso cr\u00f4nico de medica\u00e7\u00f5es laxativas. Em contrapartida, estes laxantes podem espoliar microbiota intestinal, levando a dist\u00farbios hidroeletrol\u00edticos e nutricionais. Al\u00e9m disso, seu efeito pode ser reduzido pelo uso cr\u00f4nico 35,36\nPoucos estudos avaliaram a preval\u00eancia e fatores associados \u00e0 constipa\u00e7\u00e3o na popula\u00e7\u00e3o brasileira em hemodi\u00e1lise. Caracter\u00edsticas regionais como alimenta\u00e7\u00e3o, etnia, comorbidades e, at\u00e9 mesmo, particularidades da TRS podem influenciar significativamente o\ndiagn\u00f3stico, o manejo e o impacto da presen\u00e7a deste sintoma na qualidade de vida destes indiv\u00edduos quando comparados a popula\u00e7\u00f5es de outras regi\u00f5es ou pa\u00edses. Sendo assim, o conhecimento de dados locais \u00e9 necess\u00e1rio tanto para o melhor tratamento desses pacientes, como para o desenvolvimento de pesquisas de novas op\u00e7\u00f5es terap\u00eauticas.\n2.\tREVIS\u00c3O BIBLIOGR\u00c1FICA\n2.1\tDoen\u00e7a Renal Cr\u00f4nica\nOs rins s\u00e3o \u00f3rg\u00e3os reguladores cujas principais fun\u00e7\u00f5es s\u00e3o a manuten\u00e7\u00e3o do equil\u00edbrio hidroeletrol\u00edtico, remo\u00e7\u00e3o de produtos do metabolismo e outras subst\u00e2ncias do sangue para a urina e, ainda, a secre\u00e7\u00e3o hormonal de eritropoietina, renina e 1-25 dihidroxicalciferol1,2,6.\nA DRC resulta de les\u00f5es que levam \u00e0 redu\u00e7\u00e3o da fun\u00e7\u00e3o renal, implicando no comprometimento gradual das suas fun\u00e7\u00f5es, marcado pela diminui\u00e7\u00e3o da taxa de filtra\u00e7\u00e3o glomerular (TFG). A TFG \u00e9 a medida da depura\u00e7\u00e3o de uma subst\u00e2ncia filtrada livremente pelos glom\u00e9rulos e n\u00e3o sofre reabsor\u00e7\u00e3o ou secre\u00e7\u00e3o tubular, sendo utilizada como medida padr\u00e3o da avalia\u00e7\u00e3o da fun\u00e7\u00e3o renal. Frequentemente utiliza-se a creatinina s\u00e9rica como estimativa da TFG na rotina cl\u00ednica2,7,37.\nEm 2012, a Kidney Disease Outcome Quality Initiative (KDOQI) , patrocinada pela National Kidney Foundation (NKF), atualizou suas diretrizes sobre DRC, que compreende avalia\u00e7\u00e3o, classifica\u00e7\u00e3o e estratifica\u00e7\u00e3o de risco da doen\u00e7a (Quadro 1). Foi definido como portador de DRC o indiv\u00edduo que apresente TFG&lt;60 mL/minuto/1.73m2 durante tr\u00eas meses ou mais. Nos casos de pacientes com TFG >60ml/minuto/1,73m2, a DRC ser\u00e1 diagnosticada quando associada a protein\u00faria, como um marcador de dano renal parenquimatoso.\n38\nQuadro 1: Estadiamento da doen\u00e7a renal cr\u00f4nica proposto pelo KDOQI\nEst\u00e1gios da DRC\tTaxa de Filtra\u00e7\u00e3o Glomerular*\tProtein\u00faria\n1\t> 90\tPresente\n2\t60-89\tPresente\n3a\t45-59\tPresente ou ausente\n3B\t30-44\tPresente ou ausente\n4\t15-29\tPresente ou ausente\n5\t<15\tPresente ou ausente\n*mL/min/1,73m2. Adaptado de KDOQI (2012)\nO Minist\u00e9rio da Sa\u00fade do Brasil tamb\u00e9m desenvolveu um sistema de classifica\u00e7\u00e3o da\nDRC onde os est\u00e1gios de 1 a 3 correspondem aos pacientes em manejo conservador, 4 e 5-ND\n39\n(n\u00e3o dial\u00edtico) ao est\u00e1gio pr\u00e9-dial\u00edtico e 5-D (dial\u00edtico) aos pacientes em TRS .\nO Quadro 2 apresenta os est\u00e1gios da DRC, de acordo com o Minist\u00e9rio da Sa\u00fade do\nBrasil.\nQuadro 2: Estadiamento da doen\u00e7a renal cr\u00f4nica proposto pelo Minist\u00e9rio da Sa\u00fade 39\nEst\u00e1gio\tDescri\u00e7\u00e3o\t\tTFG*\n\t1\tDano renal com TFG aumentada ou normal\t>90\n\t2\tDano renal com redu\u00e7\u00e3o leve da TFG\t60-89\n\t3A\tRedu\u00e7\u00e3o moderada da TFG\t45-59\n\t3B\tRedu\u00e7\u00e3o moderada da TFG\t30-44\n\t4\tRedu\u00e7\u00e3o grave da TFG\t15-29\n\t5-ND\tInsufici\u00eancia Renal Terminal n\u00e3o dial\u00edtica\t<15\n\t5-D\tInsufici\u00eancia Renal Terminal dial\u00edtica\t<15\nFonte: Adaptado de Diretrizes cl\u00ednicas para o cuidado ao paciente com doen\u00e7a renal cr\u00f4nica no sistema \u00fanico de sa\u00fade (BRASIL, 2014a).\nEmbora em posse destas classifica\u00e7\u00f5es bem determinadas, o diagn\u00f3stico da DRC normalmente \u00e9 tardio devido \u00e0 aus\u00eancia de sintomas nos pacientes que se encontram nos est\u00e1gios iniciais da doen\u00e7a. Elevada suspei\u00e7\u00e3o diagn\u00f3stica \u00e9 necess\u00e1ria especialmente naqueles pacientes com fatores de risco para DRC 5.\nA HAS \u00e9 a primeira causa de DRC no Brasil, presente em aproximadamente 34% dos pacientes. A DM \u00e9 a segunda condi\u00e7\u00e3o mais prevalente, encontrada em 30% dos casos40. As duas patologias s\u00e3o fatores de risco modific\u00e1veis cujo tratamento adequado \u00e9 capaz de diminuir significativamente n\u00e3o s\u00f3 a mortalidade, mas tamb\u00e9m a velocidade de progress\u00e3o da DRC4,41\nAtrav\u00e9s de suporte medicamentoso e nutricional \u00e9 poss\u00edvel retardar a progress\u00e3o da 29\ndoen\u00e7a . A partir do est\u00e1gio 5, faz-se necess\u00e1ria TRS que engloba as t\u00e9cnicas de depura\u00e7\u00e3o extra-renal por hemodi\u00e1lise (HD), di\u00e1lise peritoneal (DP) e o transplante renal (TR) .\n2.2\tEtiologia e Epidemiolog\u00eda da DRC\nA DRC deve-se principalmente a DM e HAS, mas tamb\u00e9m pode ser consequ\u00eancia de s\u00edndrome nefr\u00f3tica, rins polic\u00edsticos, glomerulopatias, lit\u00edase renal, doen\u00e7as autoimunes ou uropatia obstrutiva . O aumento da preval\u00eancia de DM tipo 2 e da expectativa m\u00e9dia de vida da popula\u00e7\u00e3o t\u00eam contribu\u00eddo para o crescimento progressivo do n\u00famero de doentes com DRC e daqueles que necessitam de TRS6.\nEm rela\u00e7\u00e3o \u00e0 mortalidade, dados de mortalidade global de 1990 colocavam a DRC na 27a posi\u00e7\u00e3o, passando a 18a em 2010 com mortalidade anual de 16,3 mortes por 100.000 habitantes , . No Brasil, segundo a Sociedade Brasileira de Nefrologia, a estimativa \u00e9 que mais de 10 milh\u00f5es de pessoas tenham a doen\u00e7a em algum est\u00e1gio. Desses, aproximadamente 120 mil est\u00e1 em di\u00e1lise, n\u00famero que cresceu mais de 50% nos \u00faltimos dez anos. Este n\u00famero representa um aumento de 31,5 mil pacientes nos \u00faltimos 5 anos, j\u00e1 que em 2011 eram 92.314 mil pacientes nessa situa\u00e7\u00e3o. A taxa de preval\u00eancia foi de 596 doentes em terapia de substitui\u00e7\u00e3o renal por milh\u00e3o de habitantes41,43; por\u00e9m, ainda que significativa, essa taxa \u00e9 muito inferior \u00e0 do Jap\u00e3o, por exemplo, onde a popula\u00e7\u00e3o \u00e9 mais idosa e registra a preval\u00eancia de 2.535 indiv\u00edduos em TRS por milh\u00e3o de habitantes 44\nJ\u00e1 a incid\u00eancia de pacientes em TRS no Brasil foi estimada em 193 doentes por milh\u00e3o de habitantes em 2016, superior a taxa de incid\u00eancia europeia, que foi de 123 indiv\u00edduos por milh\u00e3o de habitantes na mesma \u00e9poca 45.\nA associa\u00e7\u00e3o da preval\u00eancia de DRC e de pacientes em TRS est\u00e1 fortemente associada ao n\u00edvel de desenvolvimentos socioecon\u00f4mico dos pa\u00edses. Estima-se que mais de 80% de todos os pacientes que recebem tratamento para a DRC em fase dial\u00edtica est\u00e3o em pa\u00edses desenvolvidos, com alta expectativa de vida e acesso amplo ao sistema de sa\u00fade. A menor preval\u00eancia de DRC e TRS nos pa\u00edses de menor renda pode ser atribu\u00edda principalmente a menor expectativa de vida da popula\u00e7\u00e3o e a escassez de centros de tratamento de TRS, o que acarreta em \u00f3bito precoce e consequente diminui\u00e7\u00e3o da preval\u00eancia da doen\u00e7a 46,47\nDevido ao envelhecimento da popula\u00e7\u00e3o, grande parte dos doentes que fazem terapia de substitui\u00e7\u00e3o renal no mundo apresenta idade avan\u00e7ada. Nos Estados Unidos da Am\u00e9rica (EUA) quase 75% dos doentes t\u00eam idade superior a 65 anos; na Europa a m\u00e9dia de idade \u00e9 de 57 anos . No Brasil, em 2016, 32,5% dos pacientes em TRS tinham idade acima de 65 anos41.\nA Hemodi\u00e1lise (HD) \u00e9 o tratamento dial\u00edtico mais adotado no mundo49. Estima-se que mais de dois milh\u00f5es de pessoas s\u00e3o mantidas vivas por meio da HD, das quais a maioria \u00e9 tratada em apenas cinco pa\u00edses: Estados Unidos, Jap\u00e3o, Alemanha, Brasil e It\u00e1lia50.\n2.3\tHemodi\u00e1lise\nA Hemodi\u00e1lise se d\u00e1 atrav\u00e9s da retirada do sangue de um acesso vascular que \u00e9 impulsionado por uma bomba para um sistema de circula\u00e7\u00e3o extracorp\u00f3rea (m\u00e1quina de hemodi\u00e1lise) onde se encontra o dialisador (filtro). Nesse, ocorrem trocas entre o sangue e o l\u00edquido chamado de dialisato a partir de uma membrana semiperme\u00e1vel7.\nA hemodi\u00e1lise tradicional, de modo geral, \u00e9 realizada tr\u00eas vezes por semana, com dura\u00e7\u00e3o de quatro horas, fluxo de sangue de 250 a 300 mL/min e fluxo de dialisato de 500 mL/min. Al\u00e9m da di\u00e1lise propriamente, um plano individualizado de farmacoterapia e de dietoterapia deve ser adotado7,51.\nA dietoterapia na vig\u00eancia da hemodi\u00e1lise baseia-se, resumidamente, em ajustes na oferta proteica da dieta, equil\u00edbrio de minerais, especialmente f\u00f3sforo e pot\u00e1ssio, e balan\u00e7o h\u00eddrico. 52. Entre os f\u00e1rmacos frequentemente em uso por pacientes em hemodi\u00e1lise est\u00e3o os quelantes de f\u00f3sforo a base de c\u00e1lcio, utilizados para controle do metabolismo c\u00e1lcio-f\u00f3sforo. Tamb\u00e9m s\u00e3o utilizados com frequ\u00eancia a vitamina D ativada, o ferro e a eritropoietina\n53\nhumana recombinante (EPO)53\nA monitora\u00e7\u00e3o da dose de di\u00e1lise adequada a cada paciente pode ser feita pela medida dos \u00edndices de remo\u00e7\u00e3o da ureia, representados pela taxa de redu\u00e7\u00e3o da ureia (URR) e pelo Kt/V da ureia. O Kt/V representa quantas vezes a \u00e1gua corporal do paciente foi totalmente depurada de um soluto. Este deve manter-se igual ou acima de 1,2 54.\nO in\u00edcio da hemodi\u00e1lise leva o paciente a um processo de modifica\u00e7\u00f5es em suas condi\u00e7\u00f5es fisiol\u00f3gicas, nutricionais e sociais55. Dentre as complica\u00e7\u00f5es mais frequentes da DRC em TRS, est\u00e3o os processos infecciosos, dist\u00farbios do metabolismo \u00f3sseo e mineral, acidose metab\u00f3lica, hipercalemia, desequil\u00edbrio hidroeletrol\u00edtico, hipervolemia ou hipovolemia, anemia, dist\u00farbios hormonais, hiperparatireoidismo, hipertens\u00e3o arterial irregular, altera\u00e7\u00f5es de paladar, apetite e metabolismo dos nutrientes, altera\u00e7\u00f5es gastrointestinais, retardo do crescimento, infertilidade, insufici\u00eancia card\u00edaca, entre outros 2,55.\nPortanto, apesar da reconhecida fun\u00e7\u00e3o da hemodi\u00e1lise no aumento da sobrevida dos pacientes, \u00e9 importante avan\u00e7ar na promo\u00e7\u00e3o do cuidado e manuten\u00e7\u00e3o da qualidade de vida, j\u00e1 que diversos estudos mostram significativa redu\u00e7\u00e3o de indicadores de qualidade de vida nesta popula\u00e7\u00e3o23,56,57.\n2.4\tConstipa\u00e7\u00e3o Instestinal\nHabitualmente, define-se a constipa\u00e7\u00e3o intestinal como um transtorno caracterizado pela dificuldade persistente para evacuar ou uma sensa\u00e7\u00e3o de evacua\u00e7\u00e3o incompleta e/ou\nmovimentos intestinais infrequentes (a cada 3-4 dias ou mais), em aus\u00eancia de sintomas de alarme ou causas secund\u00e1rias. As diferen\u00e7as na defini\u00e7\u00e3o e as varia\u00e7\u00f5es entre os sintomas relatados dificultam a precis\u00e3o dos dados epidemiol\u00f3gicos58,59.\nA constipa\u00e7\u00e3o intestinal \u00e9 uma queixa frequente tanto em ambulat\u00f3rios cl\u00ednicos, quanto em ambiente de interna\u00e7\u00e3o hospitalar e afeta, principalmente, mulheres, idosos e pessoas de n\u00edvel socioecon\u00f3mico e educacional reduzido 60,61.\nA preval\u00eancia de CI na popula\u00e7\u00e3o em geral, encontrada na literatura, \u00e9 variada, dependendo especialemente das caracter\u00edsticas da amostra e do crit\u00e9rio de defini\u00e7\u00e3o da CI utilizado. Estudos com preval\u00eancias entre 2% e 30% est\u00e3o descritos 24,62,63 na popula\u00e7\u00e3o internacional e de 5 a 21% em pa\u00edses da Am\u00e9rica Latina 60,64 Nos EUA, por exemplo, uma revis\u00e3o realizada por Bharucha et al (20 1 3)65 considerou que a m\u00e9dia de preval\u00eancia de constipa\u00e7\u00e3o \u00e9 16% em adultos e 33,5% em indiv\u00edduos maiores de 60 anos. Na regi\u00e3o Sul do Brasil, um estudo de base populacional realizado em Pelotas-RS mostrou preval\u00eancia de constipa\u00e7\u00e3o intestinal de 26,9%. Neste mesmo estudo, as mulheres apresentaram duas vezes mais constipa\u00e7\u00e3o do que os homens (36,8% vs. 13,9%), e ainda idade e cor da pele tamb\u00e9m foram associadas estatisticamente a presen\u00e7a de CI 60. A preval\u00eancia de constipa\u00e7\u00e3o mostra-se t\u00e3o variada, possivelmente, por quest\u00f5es demogr\u00e1ficas, tamanho das amostras, m\u00e9todos e defini\u00e7\u00f5es utilizados nos diferentes estudos.\nA CI \u00e9, geralmente, resultado da soma de m\u00faltiplos fatores, desde alimentares, uso de medicamentos, inatividade f\u00edsica ou estilo de vida, at\u00e9 disfun\u00e7\u00f5es motoras prim\u00e1rias produzidas por miopatia ou neuropatia col\u00f3nica, ou ainda secund\u00e1ria a um transtorno de evacua\u00e7\u00e3o61. Segundo as diretrizes da Organiza\u00e7\u00e3o Mundial de Gastroenterologia sobre constipa\u00e7\u00e3o publicadas em 2010 (sua \u00faltima atualiza\u00e7\u00e3o) , existem alguns fatores que reconhecidamente aumentam o risco de constipa\u00e7\u00e3o, como a idade avan\u00e7ada, o sedentarismo, a depress\u00e3o e o sexo feminino. Entre as condi\u00e7\u00f5es end\u00f3crino-metab\u00f3licas associadas est\u00e3o\nDM e DRC e entre as medica\u00e7\u00f5es que predisp\u00f5e a constipa\u00e7\u00e3o est\u00e3o algumas frequentemente usadas por pacientes em TRS, como os suplementos de c\u00e1lcio e ferro, opi\u00f3des, antidepressivos e agentes anti-inflamat\u00f3rios n\u00e3o-ester\u00f3ideos.\nExistem duas caracter\u00edsticas distintas de constipa\u00e7\u00e3o intestinal e que se superp\u00f5em: os transtornos do tr\u00e2nsito e os transtornos da evacua\u00e7\u00e3o. Os primeiros podem surgir secundariamente aos segundos, e os segundos, em algumas ocasi\u00f5es, podem apresentar-se ap\u00f3s os primeiros 28,66. As principais fun\u00e7\u00f5es do c\u00f3lon est\u00e3o relacionadas a sua capacidade de absor\u00e7\u00e3o de \u00e1gua, de algumas vitaminas, eletr\u00f3litos, secre\u00e7\u00e3o de muco para lubrifica\u00e7\u00e3o das fezes, s\u00edntese de vitaminas B e K atrav\u00e9s das bact\u00e9rias col\u00f4nicas, armazenamento fecal para ser excretado e elimina\u00e7\u00e3o de res\u00edduos. Atrav\u00e9s da motilidade, ocorre a transfer\u00eancia do material fecal pelo c\u00f3lon at\u00e9 o reto e, com a movimenta\u00e7\u00e3o da musculatura (peristaltismo) do c\u00f3lon, ocorre a impuls\u00e3o do material fecal. Este processo \u00e9 involunt\u00e1rio, estando influenciado diretamente pela distens\u00e3o do l\u00famen pelas fezes. O material fecal \u00e9 constitu\u00eddo de bact\u00e9rias, \u00e1gua, gases e res\u00edduos n\u00e3o digeridos no intestino delgado. O tamanho das fezes est\u00e1 relacionado \u00e0 velocidade do tr\u00e2nsito intestinal .\nAinda, de acordo com a fisiopatologia, a constipa\u00e7\u00e3o pode ser classificada em tr\u00eas grupos: constipa\u00e7\u00e3o de tr\u00e2nsito lento, de tr\u00e2nsito normal (incluindo s\u00edndrome do intestino irrit\u00e1vel) e disfun\u00e7\u00e3o do andar p\u00e9lvico. Dois ou mais mecanismos podem contribuir para os sintomas em um mesmo paciente e em cerca de um quarto deles pode ser que nenhuma anormalidade fisiopatol\u00f3gica seja detectada , .\nA aus\u00eancia de crit\u00e9rios diagn\u00f3sticos objetivos, e a diversidade de classifica\u00e7\u00f5es, fizeram com que um grupo de especialistas organizasse um consenso para crit\u00e9rios diagn\u00f3sticos e recomenda\u00e7\u00f5es terap\u00eauticas para as desordens funcionais intestinais. Em 1980 foram, ent\u00e3o, publicados os crit\u00e9rios de Roma I que inclu\u00edram quatro sintomas chaves para diagn\u00f3stico de constipa\u00e7\u00e3o funcional68. Em 1999, ap\u00f3s a revis\u00e3o e inclus\u00e3o de dois outros\nsintomas, foram publicados os crit\u00e9rios de Roma II69. Em setembro de 2006, o comit\u00ea fez uma nova revis\u00e3o e publicou os crit\u00e9rios de Roma III .\nSegundo os crit\u00e9rios de Roma III, para o diagn\u00f3stico de constipa\u00e7\u00e3o funcional \u00e9 necess\u00e1rio apresentar dois ou mais dos seguintes sintomas: a) esfor\u00e7o evacuat\u00f3rio durante pelo menos 25% das defeca\u00e7\u00f5es; b) fezes grumosas ou duras em pelo menos 25% das defeca\u00e7\u00f5es; c) sensa\u00e7\u00e3o de evacua\u00e7\u00e3o incompleta em pelo menos 25% das defeca\u00e7\u00f5es; d) sensa\u00e7\u00e3o de obstru\u00e7\u00e3o/bloqueio anorretal das fezes em pelo menos 25% das defeca\u00e7\u00f5es; e) necessidade de manobras manuais para facilitar em pelo menos 25% das defeca\u00e7\u00f5es (por exemplo, evacua\u00e7\u00e3o com ajuda digital, apoio do assoalho p\u00e9lvico); f) menos de tr\u00eas evacua\u00e7\u00f5es por semana; g) fezes moles est\u00e3o raramente presentes sem o uso de laxantes; h) crit\u00e9rios insuficientes para S\u00edndrome do Intestino Irrit\u00e1vel. Estes crit\u00e9rios precisam estar presentes nos \u00faltimos 3 meses e ter in\u00edcio pelo menos 6 meses antes do diagn\u00f3stico69.\nEm maio de 2016, houve uma nova atualiza\u00e7\u00e3o dos crit\u00e9rios, denominada ROMA IV. Nesta atualiza\u00e7\u00e3o foram mantidos os crit\u00e9rios de diagn\u00f3stico de constipa\u00e7\u00e3o intestinal funcional, tendo havido mudan\u00e7as somente nos crit\u00e9rios para diagn\u00f3stico de outras desordens gastrointestinais funcionais . Este novo crit\u00e9rio apresenta tradu\u00e7\u00e3o validada apenas para o espanhol at\u00e9 o momento .\nAlguns outros instrumentos s\u00e3o utilizados para ajudar na classifica\u00e7\u00e3o e no tratamento de constipa\u00e7\u00e3o, entre eles destaca-se a Escala de Bristol para Consist\u00eancia de Fezes - Bristol Stool Form Scale, que foi desenvolvida e validada em 2001, adaptada e revalidada em 2008 e validada para o portugu\u00eas em 2012 (Figura 1) , , . Seu objetivo \u00e9 avaliar, de maneira descritiva, a forma do conte\u00fado fecal, utilizando m\u00e9todos gr\u00e1ficos que representam sete tipos de fezes de acordo com sua forma e consist\u00eancia. A inova\u00e7\u00e3o dessa escala \u00e9 que ela apresenta as imagens que ilustram as fezes juntamente com descri\u00e7\u00f5es precisas quanto \u00e0 forma e \u00e0 consist\u00eancia, recorrendo a exemplos facilmente reconhec\u00edveis. O paciente deve apenas\nselecionar o tipo de fezes que mais se assemelha \u00e0s suas pr\u00f3prias fezes, de acordo com a consist\u00eancia e forma . O uso da Escala de Bristol \u00e9 um m\u00e9todo diagn\u00f3stico recomendado pela WGO para diagn\u00f3stico de constipa\u00e7\u00e3o associado aos Crit\u00e9rios de ROMA. Seu uso tamb\u00e9m foi avaliado em portadores de DRC. Em um estudo com 148 pacientes com DRC avan\u00e7ada, essa ferramenta foi comparada com a percep\u00e7\u00e3o do paciente e os crit\u00e9rios ROMA III, e foi verificado, com preval\u00eancias de diagn\u00f3stico, constipa\u00e7\u00e3o de 25,7%, 46,3, e 12,3%, respectivamente, concluindo que o m\u00e9todo \u00e9 sens\u00edvel, por\u00e9m nenhum m\u00e9todo sozinho \u00e9 superior \u00e0 associa\u00e7\u00e3o de diferentes m\u00e9todos 75.\nFonte: Martinez AP, Azevedo GR.,201274\n2.4.1\tTratamento da Constipa\u00e7\u00e3o Instestinal\nV\u00e1rias op\u00e7\u00f5es de tratamento s\u00e3o propostas para o manejo da constipa\u00e7\u00e3o. Geralmente, as primeiras medidas adotadas incluem altera\u00e7\u00f5es diet\u00e9ticas, est\u00edmulo \u00e0 atividade f\u00edsica e, quando necess\u00e1rio, medidas farmacol\u00f3gicas58.\n2.4.1.1\tMedidas diet\u00e9ticas\nA introdu\u00e7\u00e3o de mais frutas, legumes, verduras e gr\u00e3os integrais na alimenta\u00e7\u00e3o cotidiana \u00e9 a primeira medida recomendada para tratar os sintomas da constipa\u00e7\u00e3o intestinal funcional, visto que esses alimentos s\u00e3o fonte de fibras 58. Em uma metan\u00e1lise de 201276, foram analisados 5 estudos com total de 1322 pacientes, onde foi avaliada a associa\u00e7\u00e3o entre o consumo de fibras e a preval\u00eancia de constipa\u00e7\u00e3o. Todos os resultados mostraram uma tend\u00eancia ou diferen\u00e7a significativa a favor do grupo de tratamento (fibras) como, por exemplo, a frequ\u00eancia de evacua\u00e7\u00f5es por semana aumentada quando comparado ao grupo placebo (OR = 1,19; IC 95%: 0,58-1,80, P&lt;0,05), chegando-se \u00e0 conclus\u00e3o de que ingest\u00e3o de fibras diet\u00e9ticas pode, seguramente, aumentar a frequ\u00eancia de fezes em pacientes com constipa\u00e7\u00e3o.\nA fibra alimentar \u00e9 constitu\u00edda de pol\u00edmeros de carboidratos, com tr\u00eas ou mais unidades monom\u00e9ricas, e mais a lignina - um pol\u00edmero de fenilpropano, sendo resistente \u00e0 a\u00e7\u00e3o das enzimas digestivas humanas77,78. Os componentes da fibra alimentar dividem-se nos seguintes grupos: polissacar\u00eddeos n\u00e3o amido, oligossacar\u00eddeos, carboidratos an\u00e1logos (amido resistente e maltodextrinas resistentes), lignina, compostos associados \u00e0 fibra alimentar (compostos fen\u00f3licos, prote\u00edna de parede celular, oxalatos, fitatos, ceras, cutina e suberina) e fibras de origem animal (quitina, quitosana, col\u00e1geno e condroitina)79.\nAs fibras s\u00e3o classificadas como fibras sol\u00faveis, como a pectina presente nas frutas, e fibras insol\u00faveis como o farelo de trigo que tem a\u00e7\u00e3o no aumento de volume do bolo fecal 77. Os efeitos ben\u00e9ficos das fibras alimentares est\u00e3o relacionados, em parte, ao fato de que uma parcela da fermenta\u00e7\u00e3o de seus componentes ocorrer no intestino grosso, o que produz impacto sobre a velocidade do tr\u00e2nsito intestinal, o pH do c\u00f3lon e a produ\u00e7\u00e3o de subprodutos com importante fun\u00e7\u00e3o fisiol\u00f3gica 80,81,82.\nNa recomenda\u00e7\u00e3o quanto ao consumo di\u00e1rio ideal de fibras para adultos no Brasil, o Minist\u00e9rio da Sa\u00fade, atrav\u00e9s do Guia Alimentar da Popula\u00e7\u00e3o Brasileira (2014) , recomenda uma ingest\u00e3o di\u00e1ria m\u00ednima de 25g de fibras para adultos, independente do sexo. Esta recomenda\u00e7\u00e3o \u00e9 id\u00eantica \u00e0 da Organiza\u00e7\u00e3o Mundial de Gastroenterologia sobre Manejo dos sintomas comuns de doen\u00e7as gastrointestinais na comunidade (2013) .\nA terap\u00eautica nutricional tamb\u00e9m pode incluir, al\u00e9m das modifica\u00e7\u00f5es alimentares j\u00e1 descritas, o uso de agentes formadores de massa, como os m\u00f3dulos de fibras (prebi\u00f3ticos), os probi\u00f3ticos (microorganismos da flora intestinal comensal) e os simbi\u00f3ticos (associa\u00e7\u00e3o de prebi\u00f3ticos e probi\u00f3ticos). O uso desses agentes \u00e9 indicado quando n\u00e3o se consegue atingir a ingesta sugerida de fibras (25g) . Atualmente, o uso destes m\u00f3dulos vem sendo crescentemente estudados como alternativa n\u00e3o medicamentosa no manejo da constipa\u00e7\u00e3o85,86. Em contrapartida a ades\u00e3o a esses m\u00f3dulos pode ser afetada pelos relatos de aumento da flatul\u00eancia, distens\u00e3o abdominal, e sensa\u00e7\u00e3o de plenitude. .\n2.4.1.2\tPr\u00e1tica de atividade f\u00edsica\nSabe-se que o sedentarismo e imobilidade contribuem para constipa\u00e7\u00e3o intestinal65,88. O n\u00edvel de atividade f\u00edsica tamb\u00e9m pode influenciar na motilidade gastrointestinal, j\u00e1 que o exerc\u00edcio f\u00edsico proporciona movimentos no intestino grosso e mudan\u00e7as hormonais que\npromovem efeito mec\u00e2nico no intestino favorecendo o aumento do peristaltismo; portanto, o\n89 desenvolvimento da musculatura abdominal ir\u00e1 atuar no favorecimento do ato da defeca\u00e7\u00e3o .\nEm pacientes com constipa\u00e7\u00e3o idiop\u00e1tica cr\u00f4nica, a atividade f\u00edsica moderada (30-60 min por dia) melhora a consist\u00eancia das fezes 90. No caso dos pacientes com constipa\u00e7\u00e3o induzida por drogas, deve ser considerado se o medicamento pode ser substitu\u00eddo por outro menos propenso a causar constipa\u00e7\u00e3o, por\u00e9m, mesmo na impossibilidade de substitui\u00e7\u00e3o da medica\u00e7\u00e3o, j\u00e1 s\u00e3o observadas melhoras discretas na preval\u00eancia de constipa\u00e7\u00e3o pela pr\u00e1tica regular de atividade f\u00edsica 91.\n2.4.1.3\tUso de laxativos\nO uso de medicamentos laxativos tem como objetivo promover o carreamento de l\u00edquidos para o l\u00famen intestinal, aumentar o volume e promover o amolecimento do bolo fecal, estimulando, assim, o peristaltismo intestinal . A utiliza\u00e7\u00e3o de laxantes deve ser espor\u00e1dica e de acordo com prescri\u00e7\u00e3o m\u00e9dica. O recurso aos laxantes para tratamento da obstipa\u00e7\u00e3o deve ser feito em associa\u00e7\u00e3o \u00e0s medidas n\u00e3o farmacol\u00f3gicas, quando estas n\u00e3o s\u00e3o suficientes. Desse modo, a utiliza\u00e7\u00e3o deste tipo de medicamentos deve ser tempor\u00e1ria, durante um curto per\u00edodo de tempo e para situa\u00e7\u00f5es pontuais que n\u00e3o estejam associadas a outras patologias de origem gastrointestinal .\nUm ensaio cl\u00ednico americano recentemente publicado, que buscava avaliar a efici\u00eancia de terap\u00eauticas convencionais, ou seja, suplementos de fibras em pacientes em di\u00e1lise peritoneal selecionou uma amostra de 107 pacientes e encontrou uma preval\u00eancia de 38,3% de uso de laxantes rotineiramente em indiv\u00edduos que sequer tinham diagn\u00f3stico de constipa\u00e7\u00e3o por algum crit\u00e9rio .\nExistem v\u00e1rios tipos de laxantes que, de acordo com o mecanismo de a\u00e7\u00e3o, podem ser classificados em laxantes expansores do volume fecal, salinos, osm\u00f3ticos, emolientes, lubrificantes e estimulantes ou de contato , .\nAlguns efeitos colaterais do uso de determinados laxantes precisam ser considerados. Por exemplo, os laxantes lubrificantes, como o \u00f3leo mineral, quando usado por um per\u00edodo prolongado, ou em doses excessivas, pode originar o gotejamento anal que, para al\u00e9m de ser desagrad\u00e1vel, pode tamb\u00e9m causar prurido anal, hemorroidas e outras doen\u00e7as perianais .\nOs laxantes salinos, como o manitol e o leite de magn\u00e9sio, est\u00e3o normalmente associados a desequil\u00edbrios hidroelectrol\u00edticos, raz\u00e3o pela qual a sua utiliza\u00e7\u00e3o exige grande precau\u00e7\u00e3o e dever\u00e1 ocorrer durante um curto per\u00edodo de tempo. Os laxantes salinos podem ser utilizados sob a forma de enema .\nJ\u00e1 o uso de laxantes osm\u00f3ticos, como a lactulose, por exemplo, pode estar associado a n\u00e1useas, c\u00f3licas abdominais, flatul\u00eancia, meteorismo ou diarreia, pelo que \u00e9 fundamental a\n93\ningest\u00e3o de \u00e1gua para preven\u00e7\u00e3o de poss\u00edvel desidrata\u00e7\u00e3o .\nAssim, a administra\u00e7\u00e3o dos laxantes de modo geral deve ser por curtos per\u00edodos de tempo, em pequenas quantidades ou em administra\u00e7\u00f5es mais espa\u00e7adas92,93.\n2.5\tConstipa\u00e7\u00e3o intestinal e doen\u00e7a renal cr\u00f4nica\nA constipa\u00e7\u00e3o intestinal (CI) foi o terceiro sintoma gastrointestinal mais prevalente em portadores de DRC terminal (est\u00e1gio 5), em TRS, sendo relatada por 53% dos pacientes em uma revis\u00e3o sistem\u00e1tica que analisou 59 estudos, ficando atr\u00e1s apenas da fadiga (71%) e do prurido (55%)16. Quanto \u00e0 preval\u00eancia de constipa\u00e7\u00e3o nos diferentes tipos de TRS, um estudo realizado com pacientes em TRS no Jap\u00e3o, que mostrou preval\u00eancia de 63% de constipa\u00e7\u00e3o nos indiv\u00edduos em HD, observou que esse sintoma foi tr\u00eas vezes maior do que nos pacientes\n21\nda mesma popula\u00e7\u00e3o em di\u00e1lise peritoneal (28,9%) . Diferen\u00e7a semelhante foi descrita em outros estudos15,18,22.\nNo Brasil, um estudo recentemente publicado por Ramos e colaboradores (2015)94 avaliou CI em 290 pacientes com DRC em hemodi\u00e1lise, tendo encontrado uma preval\u00eancia de 32,8% de CI segundo os crit\u00e9rios de ROMA III. Outro estudo brasileiro , que investigou a constipa\u00e7\u00e3o em 5 centros de di\u00e1lise no pa\u00eds (N= 448), encontrou preval\u00eancia semelhante de 33,5% no grupo de pacientes em HD e de 26,6% naqueles em di\u00e1lise peritoneal, diferen\u00e7a muito inferior ao encontrado no estudo internacional citado no par\u00e1grafo anterior. Suspeita-se, portanto, que diferen\u00e7as \u00e9tnicas, de h\u00e1bitos alimentares, de prescri\u00e7\u00e3o medicamentosa, al\u00e9m de diferen\u00e7as nas amostras estudadas, podem justificar a variabilidade na preval\u00eancia deste sintoma entre os estudos em doentes renais cr\u00f4nicos.\nA origem da CI no paciente em di\u00e1lise, al\u00e9m dos usuais, pode ser acrescida de v\u00e1rios fatores inerentes a essa popula\u00e7\u00e3o, como h\u00e1bitos alimentares, devido a redu\u00e7\u00e3o de ingest\u00e3o de fibras e de l\u00edquidos, fatores emocionais, patol\u00f3gicos, f\u00edsicos e medicamentosos19,20,29,30.\n\u00c9 reconhecido que o consumo de fibras melhora a constipa\u00e7\u00e3o ao aumentar a massa fecal, o que estimula a intensidade da atividade intestinal, como j\u00e1 mencionado do item anterior . Na popula\u00e7\u00e3o n\u00e3o renal, uma clara resposta \u00e0 dose foi demonstrada entre a ingest\u00e3o de fibras e a produ\u00e7\u00e3o fecal95,96.\nO consumo de fibras tamb\u00e9m est\u00e1 associado a uma s\u00e9rie de benef\u00edcios cl\u00ednicos e de sa\u00fade, como melhora da toler\u00e2ncia \u00e0 glicose, n\u00edveis lip\u00eddicos melhorados e saciedade precoce97. Uma resposta semelhante pode ser esperada em pacientes em TRS, mas sua recomenda\u00e7\u00e3o \u00e9 reservada pelas provis\u00f5es diet\u00e9ticas colocadas sobre estes pacientes devido \u00e0s pr\u00f3prias limita\u00e7\u00f5es da doen\u00e7a renal, e/ou tratamento. Recomenda-se, aos pacientes nesta condi\u00e7\u00e3o, que sigam uma dieta rica em prote\u00ednas, hipocal\u00eamica, e hipofosfat\u00eamica e, portanto, \u00e9 necess\u00e1rio reduzir os alimentos contendo fosfato e pot\u00e1ssio.\nMuitas vezes os pacientes s\u00e3o confrontados com recomenda\u00e7\u00f5es conflitantes, uma vez que muitos alimentos de alto n\u00edvel de fibras tamb\u00e9m s\u00e3o ricos em pot\u00e1ssio e f\u00f3sforo, o que resulta em que esses alimentos sejam desencorajados em pacientes com doen\u00e7a renal avan\u00e7ada , . Por\u00e9m, um ensaio cl\u00ednico realizado por Sutton e colaborares (2007) avaliou a efici\u00eancia dos m\u00f3dulos de fibras diet\u00e9ticas em substitui\u00e7\u00e3o ao uso de laxantes em 23 pacientes em di\u00e1lise peritoneal, que usaram recorrentemente este artif\u00edcio para tratamento de constipa\u00e7\u00e3o, e observou que 73,9% das pacientes conseguiu substituir a utiliza\u00e7\u00e3o dos laxativos pelo m\u00f3dulo, com melhora dos sintomas e sem efeitos sobre os n\u00edveis nas an\u00e1lises bioqu\u00edmicas como o pot\u00e1ssio, por exemplo. Esta conclus\u00e3o foi novamente confirmada em outro ensaio cl\u00ednico multic\u00eantrico mais atual realizado pelo mesmo grupo de pesquisadores (n=41)32\nJ\u00e1 entre as medica\u00e7\u00f5es utilizadas por essa popula\u00e7\u00e3o que possam estar associadas com constipa\u00e7\u00e3o, destaca-se o Carbonato de C\u00e1lcio, que \u00e9 um quelante do f\u00f3sforo frequentemente utilizado por pacientes em hemodi\u00e1lise, j\u00e1 que esta \u00e9 pouco eficiente na remo\u00e7\u00e3o deste mineral. A restri\u00e7\u00e3o da ingest\u00e3o de f\u00f3sforo precisa ser recomendada com cautela, pois suas maiores fontes tamb\u00e9m s\u00e3o as maiores fontes de prote\u00ednas, um macronutriente que deve ser estimulado na dieta desta popula\u00e7\u00e3o. Devido a esse contraponto, \u00e9 recomendado aos pacientes em terapia renal substitutiva o uso cont\u00ednuo de quelantes de f\u00f3sforo, os quais cont\u00eam compostos que se ligam ao f\u00f3sforo do alimento, inibindo sua absor\u00e7\u00e3o intestinal. O Carbonato de C\u00e1lcio \u00e9 um dos mais comumente utilizados, em raz\u00e3o de sua efici\u00eancia neste prop\u00f3sito e seu baixo custo99,100.\nNo entanto, o uso cont\u00ednuo e de doses elevadas desta medica\u00e7\u00e3o pode levar a n\u00edveis aumentados de c\u00e1lcio no sangue. As consequ\u00eancias da hipercalcemia, por sua vez, s\u00e3o graves, podendo causar precipita\u00e7\u00e3o de c\u00e1lcio nos tecidos moles, hipertens\u00e3o, prurido, agita\u00e7\u00e3o e calcifica\u00e7\u00f5es das art\u00e9rias coron\u00e1rias e aorta. Sintomas menos graves, por\u00e9m, n\u00e3o menos\nimportantes em termos de qualidade de vida, como \u00e9 o caso da constipa\u00e7\u00e3o, que tamb\u00e9m est\u00e1 entre os sintomas da hipercalcemia29,30,100.\nAtualmente, est\u00e3o dispon\u00edveis quelantes de f\u00f3sforo igualmente eficazes para o prop\u00f3sito principal, por\u00e9m sem c\u00e1lcio em sua composi\u00e7\u00e3o, como o Cloridrato de Sevelamer. Entretanto, devido ao seu alto custo quando comparado ao carbonato de c\u00e1lcio, este acaba tendo seu uso limitado, permanecendo, assim, o carbonato de c\u00e1lcio como o quelante de f\u00f3sforo mais utilizado19,99.\nA DM tamb\u00e9m tem sido associada \u00e0 CI e, considerando que a DM \u00e9 a segunda etiologia mais frequente para DRC43, \u00e9 fundamental compreeender sua pontecial rela\u00e7\u00e3o com a presen\u00e7a do sintoma. Um estudo japon\u00eas101 realizado com 4 mil volunt\u00e1rios n\u00e3o diab\u00e9ticos (n=4135) e 603 diab\u00e9ticos que foram realizar colonoscopia em um determinado hospital monstrou associa\u00e7\u00e3o positiva entre o diabetes e constipa\u00e7\u00e3o (OR = 1.57, IC: 1.33-1.85, P &lt;0.01) e fezes endurecidas (OR = 1,56, IC: 1,33-1,84, P&lt;0,01), quando descartadas outras doen\u00e7as gastrointestinais. Neste estudo, houve associa\u00e7\u00e3o positiva entre a hemoglobina glicada elevada (>8,0%) e as nefropatia diab\u00e9tica, avaliadapelos n\u00edveis de creatinina, com a constipa\u00e7\u00e3o. Possivelmente, a hiperglicemia possa estar diretamente associada \u00e0 piora da motilidade digestiva102,103,104, al\u00e9m da neuropatia di\u00e1b\u00e9tica que, quando presente, retarda o tempo de transito col\u00f4nico e, portanto, tamb\u00e9m est\u00e1 associada \u00e0 constipa\u00e7\u00e3o 105.\nOutro fator potencialmente associado \u00e0 constipa\u00e7\u00e3o em pacientes portadores de DRC, especialmente em TRS, \u00e9 a altera\u00e7\u00e3o da microbiota intestinal (MI)106,107. Estudos em portadores de DRC revelam que, pela pr\u00f3pria caracter\u00edstica da doen\u00e7a, os indiv\u00edduos acometidos pela mesma apresentam altera\u00e7\u00f5es MI 107,108,109 o mecanismo das altera\u00e7\u00f5esainda n\u00e3o \u00e9 totalmente esclarecido, mas provavelmente est\u00e1 relacionado \u00e0 produ\u00e7\u00e3o de toxinas ur\u00eamicas, entre elas o sulfato de p-cresol e o sulfato de indoxyl, que, por sua vez, podem acelerar o avan\u00e7o da DRC em indiv\u00edduos pr\u00e9 -dial\u00edticos109,110,111. A maioria destas mudan\u00e7as\nocorre no \u00edleo e no c\u00f3lon, com altera\u00e7\u00f5es que interferem muito al\u00e9m do tr\u00e2nsito intestinal apenas112,113.\nEnsaios cl\u00ednicos t\u00eam demonstrando efeito ben\u00e9fico do uso de repositores de microbiota intestinal, como m\u00f3dulos de probi\u00f3ticos e simbi\u00f3ticos (bact\u00e9rias comensais e probi\u00f3ticos), nos indiv\u00edduos com DRC, especialmente no manejo da s\u00edndrome ur\u00eamica, para atenua\u00e7\u00e3o da progress\u00e3o da doen\u00e7a, redu\u00e7\u00e3o de marcadores inflamat\u00f3rios e redu\u00e7\u00e3o de risco de doen\u00e7as cardiovasculares associadas106,114,115,116,117,118. Observa-se, por\u00e9m, que s\u00e3o escassos os estudos que investigaram o impacto destas suplementa\u00e7\u00f5es no tr\u00e2nsito intestinal desta popula\u00e7\u00e3o, embora tal interven\u00e7\u00e3o provavelmente tenha impacto no tr\u00e2nsito. Desfechos secund\u00e1rios de alguns estudos mostram altera\u00e7\u00e3o na caracter\u00edstica das fezes dos participantes, observando-se um maior volume e frequ\u00eancia de fezes em pacientes em uso de simbi\u00f3ticos 119,120,121\nUm pequeno estudo preliminar realizado por Nakabayashi e colaboradores115 com 9 pacientes em hemodi\u00e1lise teve como objetivo avaliar o efeito de uma interven\u00e7\u00e3o de quatro semanas de simbi\u00f3ticos sobre os n\u00edveis s\u00e9ricos de sulfato de p-cresol, que \u00e9 uma toxina ur\u00eamica marcadora de status intestinal, analisando os n\u00edveis deste marcador antes e depois da interven\u00e7\u00e3o e tamb\u00e9m seu efeito sobre a carater\u00edstica e frequ\u00eancia das fezes. Verificou-se, dessa forma, que a toxina ur\u00eamica, p-cresol, estava associada \u00e0 constipa\u00e7\u00e3o (p=0,03) e que o tratamento com simbi\u00f3ticos resultou na normaliza\u00e7\u00e3o das evacua\u00e7\u00f5es e na diminui\u00e7\u00e3o dos n\u00edveis s\u00e9ricos de p-cresol em pacientes com HD.\nO racioc\u00ednio para o uso de simbi\u00f3ticos \u00e9 que a presen\u00e7a de prebi\u00f3ticos melhora a sobreviv\u00eancia dos probi\u00f3ticos durante o tr\u00e2nsito atrav\u00e9s do trato digestivo superior. Al\u00e9m disso, os prebi\u00f3ticos favorecem os probi\u00f3ticos intestinais na coloniza\u00e7\u00e3o, estimulando seu crescimento, bem como a crescimento de esp\u00e9cies bacterianas residentes que, por sua vez,\npodem ajudar a microbiota ingerida, sendo, portanto, uma promissora oportunidade\n122 terap\u00eautica para esse sintoma nos portadores de DRC .\n3.\tJUSTIFICATIVA\nEmbora a constipa\u00e7\u00e3o seja um sintoma comum em pacientes em hemodi\u00e1lise, dados sobre a preval\u00eancia de constipa\u00e7\u00e3o na popula\u00e7\u00e3o brasileira ainda s\u00e3o limitados. A variabilidade da preval\u00eancia encontrada em diferentes amostras de pacientes em hemodi\u00e1lise, caracter\u00edsticas sociodemogr\u00e1ficas distintas e particularidades regionais de tratamento justificam a necessidade do conhecimento de dados locais. O conhecimento da preval\u00eancia e dos fatores associados localmente \u00e0 constipa\u00e7\u00e3o s\u00e3o necess\u00e1rios para o desenvolvimento de estrat\u00e9gias para o diagn\u00f3stico e tratamento desta morbidade. Paralelamente, conhecer estes dados \u00e9 necess\u00e1rio para o desenvolvimento de estudos de interven\u00e7\u00e3o (ECR).\nProjeto de pesquisa j\u00e1 elaborado e aprovado pelo CEP com uso de simbi\u00f3ticos para o manejo da constipa\u00e7\u00e3o nessa popula\u00e7\u00e3o utilizar\u00e1 os dados do presente estudo como linha de base. Nome do projeto: \u201cEfeito da administra\u00e7\u00e3o oral de simbi\u00f3ticos no h\u00e1bito intestinal e na qualidade de vida de indiv\u00edduos com doen\u00e7a renal cr\u00f4nica em hemodi\u00e1lise: um ensaio cl\u00ednico randomizado (HEMOSIM)\u201d, aprovado pelo Comit\u00ea de \u00c9tica em Pesquisa do Hospital Moinhos de Vento, sob o parecer n\u00famero 1.507.301, em abril de 2016.\n4.\tQUEST\u00c3O DE PESQUISA\nQual a preval\u00eancia de Constipa\u00e7\u00e3o Intestinal em pacientes em hemodi\u00e1lise e seus fatores associados?\n5.\tHIP\u00d3TESE\nCaracter\u00edsticas sociodemogr\u00e1ficas (sexo feminino, maior idade), comportamentais (sedentarismo), comorbidades (DM), medicamentos (carbonato de c\u00e1lcio) e h\u00e1bitos alimentares (consumo de fibras&lt;25g) est\u00e3o associdadas a uma maior preval\u00eancia de constipa\u00e7\u00e3o em pacientes em hemodi\u00e1lise.\n6.\tOBJETIVOS\n6.1\tObjetivo Geral\nAvaliar a preval\u00eancia e fatores associados \u00e0 constipa\u00e7\u00e3o intestinal em pacientes em hemodi\u00e1lise em um hospital privado do sul do Brasil.\n6.2\tObjetivos Espec\u00edficos\n\u2022\tIdentificar a preval\u00eancia de constipa\u00e7\u00e3o na Unidade de Hemodi\u00e1lise do Hospital Moinhos de Vento em Porto Alegre, Brasil.\n\u2022\tIdentificar caracter\u00edsticas sociodemogr\u00e1ficas e comportamentais, comorbidades e medicamentos associados \u00e0 constipa\u00e7\u00e3o em pacientes em hemodi\u00e1lise.\n\u2022\tIdentificar, atrav\u00e9s de registro alimentar, a associa\u00e7\u00e3o entre o consumo de fibras na dieta com a preval\u00eancia de constipa\u00e7\u00e3o.\n7.\tARTIGO\nFormatado para o peri\u00f3dico: DIGESTIVE AND LIVER DISEASES\nTITLE:\nHIGH PREVALENCE OF CONSTIPATION AND ASSOCIATED FACTORS IN\nPATIENTS ON HEMODIALYSIS\nAuthors:\nEtielle Pereira Sonaglio, Nutritionist1,2\nFernando Herz Wolff, MD, PhD1,2\n1Graduate Program in Gastroenterology and Hepatology, Faculdade de Medicina,\nUniversidade Federal do Rio Grande do Sul, Brazil\nHospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil\nPostal Address:\nFaculdade de Medicina da Universidade Federal do Rio Grande do Sul\nPrograma de P\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias em Gastroenterologia e Hepatolgia\nRua Ramiro Barcelos, 2400 - 2\u00b0 andar - Bairro Santana\nCEP 90035-003-Porto Alegre/Rio Grande do Sul - Brazil\nTelephone numbers and e-mail addresses:\nEtielle Pereira Sonaglio: (+55) 51 98222 2234 - etiellesonaglio@gmail.com\nFernando Herz Wolff: (+55) 51 99249 0979 - fhwolff@gmail.com\nSource of Finance: None.\nWord count: 3817 words without tables, 4317 with tables\nAbstract: 193 words\nKeywords: Constipation, Functional Constipation, Prevalence, Chronic kidney disease, Hemodialysis.\nAbstract\nConstipation is considered one of the most prevalent symptoms in patients with Chronic Kidney Disease. This cross-sectional study recruited 57 hemodialysis patients. A questionnaire was used to collect sociodemographic and clinical data potentially associated with constipation, which was defined using the ROMA III criteria and patients' own perception of constipation. According to ROMA III, 49.1% (n= 28) of the participants were classified as constipated and 36.8% (n=21) of the patients reported perceived \u201cstraining or difficulty evacuating\u201d. Agreement between patients' own perception and ROMA III was observed in 34 (59.6%) cases. Investigation of factors potentially associated with constipation detected that physical inactivity (Prevalence ratio 53.4; Fisher's exact test p = 0.052) and female sex (Prevalence ratio 1.6; PearsonA p = 0.07) exhibited tendencies towards a significant association. However, there were no significant associations between constipation and educational level, age group, use of calcium carbonate, presence of diabetes, nutritional status, or current fiber consumption. Use of the ROMA III criteria diagnoses a higher number of cases of constipation than patients' own perception alone. Considering its high prevalence and its impact on well-being, whether patients have constipation should be routinely investigated in this population, to enable correct diagnosis and management.\nINTRODUTION\nConstipation is one of the most common gastrointestinal symptoms affecting people with Chronic Kidney Disease (CKD), with prevalence ranging from 14.2% to 71.7%, in different samples of patients on Renal Replacement Therapy (RRT).1,2,3,4 The variability of constipation prevalence in this population may be affected by the different sociodemographic characteristics of samples, by regional differences in treatment, or even by differences in the methods used to diagnose the symptom, which very often employ patients' own perception as criterion, whereas others use validated instruments such as the ROMA.5,6,7,8,9\nThe origin of constipation in patients on dialysis can be influenced by several factors inherent to this population, such as specific details of their dietary habits, which involve reduced intake of total fibers and water; emotional factors; inactivity; and continuous-use medication, such as calcium carbonate, which is widely used in this population to maintain adequate phosphorus serum levels.2,4,5,10 More recently, it has been suggested that the altered intestinal microbiota observed in this population, possibly because of production of uremic toxins, are also part of the etiology of constipation in CKD. , ,\nDiabetes Mellitus (DM) has also been associated with prevalence of constipation. Since DM is the second most frequent etiology of CKD,14 it is important to understand its potential relationship with presence of the symptom. Probably, hyperglycemia may be directly associated with worsening of digestive motility,15 in addition to diabetic neuropathy which, when present, increases the time taken for colonic transit, contributing to intestinal constipation.16\nConventional measures that are usually employed to manage constipation in the general population are of limited applicability to patients on hemodialysis,4 whether because of liquids restrictions to which the majority of these people are subject, or because they are\n17\nunable to achieve the recommended intake of 25g of fiber per day. This limitation is\nimposed by the restriction on potassium intake that is necessary in this population, since this\n18\nmineral is abundant in foods that are rich in fiber.\nIt is therefore observed in clinical practice that treatment of these patients often resorts to chronic laxative use.19 While they are potentially beneficial over the short term, they normally exhibit reduced effect over chronic use and when they do accelerate intestinal transit, they deplete the normal intestinal flora, which can lead to hydroelectrolytic disorders.20,21,22\nFew studies have assessed the prevalence and factors associated with constipation in the Brazilian hemodialysis patient population. ,, Regional characteristics such as food, ethnicity, comorbidities, and even the specific details of RRT, may have a significant influence on diagnosis, on management, and on the impact this symptom has on the quality of life of these people, when compared with populations in other regions or countries. Knowledge of local data is therefore necessary both to improve the treatment of these patients and to enable research into new treatment options.\nMATERIALS AND METHODS\nDesign: Cross-sectional study\nParticipants: From April 2016 to February 2017, all patients on hemodialysis at the Dialysis Unit of the Hospital Moinhos de Vento were evaluated. This is a private hospital in Porto Alegre, the South of Brazil, that exclusively treats private patients and patients from the supplementary health care system. Patients of both genders, over the age of 18 years, on dialysis for more than 3 months, who were not inpatients at the time of the interview and had not been in hospital for more than 3 out of the preceding 6 months were eligible. Patients were excluded if they were neurologically or psychiatrically incapable of responding to the questionnaire.\nEthical considerations: The study was approved by the Research Ethics Committee at the Hospital Moinhos de Vento, Brazil (protocol number 1.507.301). All potential participants were informed about the study, including benefits, discomfort and risks, and those who agreed to take part signed informed consent forms.\nDefinition and measurement of study variables\nDiagnosis of constipation: The ROMA III criteria , were used for constipation diagnosis. According to these criteria, at least two of the following symptoms are needed for a diagnosis of constipation: a) straining to evacuate during at least 25% of defecations; b) lumpy or hard stools in at least 25% of defecations; c) sensation of incomplete evacuation in at least 25% of defecations; d) Sensation of anorectal obstruction/blockage of stools in at least 25% of defecations; e) need for manual maneuvers to facilitate at least 25% of defecations (for example, digital evacuation, support of the pelvic floor), f) less than three evacuations per week; g) soft stools are rarely present without use of laxatives; h) insufficient criteria for irritable bowel syndrome. These criteria must be present for the previous 3 months and have onset at least 6 months before diagnosis.\nAdditionally, the Bristol Stool Form Scale was also used.26 This is a validated instrument, used in a version translated and adapted for Portuguese, that classifies stools into seven categories, presented to the patient using illustrative figures with corresponding descriptions. The instrument is used by requesting the patient to indicate the form their stools have most resembled during the previous 3 months. To supplement these instruments, at the same time, the patient was asked for their own perception of gastrointestinal symptoms such as: current need for effort to defecate, abdominal pains, abdominal distension, nausea, vomiting, and flatulance. If they reported any of these, they were asked whether these symptoms had an impact on their wellbeing.\nSociodemographic and Health Questionnaire: A semi-structured questionnaire developed by the authors was used to collect sociodemographic data such as age, gender, partnership status, and educational level in years of study. The same questionnaire covered clinical data, details related to CKD etiology, length of time on a regular hemodialysis program, and use of chelating agents and laxatives. Use of medications, such as chelating agents and laxatives, were confirmed by review of the electronic patient records, covering posology, and frequency of use.\nPhysical activity: Classification of participants into those who did or did not practice physical activity was based on frequency and duration of physical activities reported. Those who reported a frequency of three times per week or more, with a minimum duration of 30 minutes, were defined as active. Biochemical analyses: Biochemical analyses are conducted regularly, in compliance with national legislation and international recommendations for hemodialysis services. , These data were therefore available for consultation in patients' medical records. No additional tests were needed for the purposes of this study. Samples for biochemical analyses are taken monthly at the 2nd dialysis session of the 2nd week of the month and blood samples are taken at the start and end of the HD session, with the objective of monitoring the progress of patients in treatment. For patients with vascular access (fistula or prosthesis), samples are taken at the time of puncture, before starting HD; for patients with central catheters, the procedure is similar, but no puncture is necessary. Disposable materials are used and blood is drawn into tubes that have been selected and labeled in advance. All analyses were performed at a local, certified, laboratory (Laborat\u00f3rio Weinmann, Porto Alegre, Brazil). For this study, results for Hemoglobin, Creatinine, Urea, Albumin, Potassium, and Phosphorus were used for the month in which patients were interviewed.\nAnthropometric measurements: For patients on hemodialysis, the weight used as a reference is dry weight. Dry weight is a value estimated by the nephrologist. In order to define the value, weight measured at the end of dialysis is considered in the light of clinical parameters, such as arterial blood pressure, intra-dialysis symptoms, presence of peripheral edema or pulmonary congestion, cramps or other signs of fluids imbalance. Height is measured by an examiner trained in the unit's nutritional assessment routine, using the stadiometer of a Filizola\u00ae balance. Both results were taken from the patient record for the day the interview was conducted.\nHeight and dry weight were used to calculate body mass index (BMI), expressed in\n2 2\nkg/m , according to the formula Weight/Height . The resulting BMI was classified according 30\t2\t2\nto the WHO standards, by which&lt;18.5 kg/m is considered malnourished, 18.5-24.9 kg/m healthy weight, 25-29.9 kg/m overweight, and > 30 kg/m is defined as obese.\nDaily Intake: Data for analysis of dietary fiber intake were collected using the direct assessment method, using 2- day-diet- record . Patients were requested not to change their normal dietary habits while recording on 2 days, one dialysis day and one day without dialysis, everything they consumed, including supplements. After detailed instructions had been given by the researchers, the participants were given a printed sheet and instructions on how to fill it out for each day of the food diary. It was recommended that they recorded what they ate immediately afterwards, to minimize omissions.\nThe food diary results were used to calculate the nutritional content of the diet, divided into carbohydrates, proteins, lipids, and fibers, using DietWin\u00ae software (Fator Digital, Brazil), which takes the composition of foods from the Brazilian table of the nutritional\n31\ncomposition of foods.\nSTATISTICAL ANALYSIS\nSample size was calculated using WinPepi\u00ae Version 2.82. Considering the population on chronic dialysis at the center at the time of the study as 75 participants, an estimated frequency of constipation of 40%, with tolerable variation of 15%, and a 95% confidence interval, a sample size of 59 patients was calculated.\nThe database was constructed using Microsoft Excel\u00ae and statistical analysis was performed using SPSS\u00ae (Statistical Package for Social Sciences), version 20. Prevalence and categorical variables were expressed as percentages and the statistical significance of associations was analyzed using Fisher's exact test or Pearson's chi-square test. Continuous variables were expressed as means and standard deviations and Student's t test was used to determine significance levels. Results with p<0.05 were considered statistically significant.\nRESULTS\nSeventy-five patients had been on hemodialysis for CKD for over 90 days at the Dialysis Center during the study period. Of these, 57 met the inclusion criteria The majority of patients (64.9%, n=37) were male and mean age was 70.8 \u00b111.5 years (range: 37-94 years), and 71.9% (n= 41) were at least 65 years old. Table 1 lists the general characteristics of the sample.\nTwenty-eight patients (49.1%) were diagnosed as constipated according to the ROMA III classification. Table 2 shows details of the characteristics of stools according to the Bristol Stool Form Scale. Stools with a solid consistency were reported most often. Type 3 was most frequently described by 40.4% of the patients (n=23), followed by types 2 and 4, with 19.3% each.\nThere was a higher prevalence of intestinal constipation among women (65%; n = 13) than men (65% vs. 40.5%; p = 0.07), which, although not significant, reveals a tendency to\nhigher female prevalence. As expected, patients who reported being physically active exhibited a lower prevalence of constipation, and this difference exhibited a tendency to significance (0 vs. 53.8%; p = 0.05). However, there were no significant differences in the prevalence of constipation related to diabetes, educational level, use of phosphate binders, type of phosphate binder, age, or nutritional status (Table 3).\nAs mentioned above, and against expectation, we did not detect significant differences in use of calcium carbonate between the constipation and no constipation groups. The majority of patients (61.4%, n=35) used calcium-based phosphate binders (Calcium Carbonate), while Sevelamer Hydrochloride was used by six patients (10.5%). Constipation was diagnosed in 57.1% of the patients who took calcium carbonate, while among the patients who only took sevelamer hydrochloride, this prevalence was 33.3%. The prevalence of constipation among patients who used both chelating agents was 50% (p = 0.5).\nThirteen of the 57 patients studied (22.8%) reported that they were currently using laxatives, three of whom were using lubricant laxatives (23.1%) and nine irritant laxatives (69.2%). One patient was unable to provide the laxative type (7.7%). Summing current and previous use of laxatives, 34 (59.6%) patients responded in the affirmative to using laxatives. Twenty-four of the 28 constipated patients (85.7%) stated they were regularly using or had previously used laxatives. As would be expected, there was a significant difference in laxative use between constipated and not constipated patients (82.1 vs. 17.9%; p = 0.001).\nWith relation to patients' own perceptions of their gastrointestinal symptoms, flatulence, abdominal pains, and abdominal distension were the symptoms most often reported by constipated patients, whether defined as such by their own perception or by ROMA III. When asked for their own perceptions, 21/57 (36.8%) reported \u201cstraining or difficulty evacuating\u201d. Agreement between patients' own perceptions of \u201cstraining or difficulty evacuating\u201d and constipation according to ROMA III criteria was observed in 34\n(59.6%) participants. It was also observed that just 61.9% (n = 13) of the patients classified as constipated by ROMA III reported difficulty evacuating. (Table 4). Seventeen of the 28 constipated patients in the sample (77.3%) stated that gastrointestinal symptoms had an interference on their well-being, whereas just 5 of the 29 patients without constipation (22.7%) did so (p = 0.01).\nOnly 35 (61.4%) of the food diaries that were given to all of the study participants to enable analysis of their nutritional intake were returned filled out. Of these, only 26 contained satisfactory records that could be used for analysis,, containing sufficient information to calculate the nutritional content of the diet. Satisfactory food diaries were therefore available for just 45.6% of the sample studied.\nConsidering the records for these 26 patients, it was observed that mean intake of fiber in the population was a little over half the recommended fiber requirement of 25g/day. Mean fiber intake was low, but no significant difference was observed between constipated and not constipated participants (13.1 vs. 14.8g/day, p = 0.5). Table 6 lists the compositions of the principal macronutrients in the sample's diets.\nNo statistically significant differences between constipated and not constipated patients were observed in the results of routine laboratory tests for urea, creatinine, potassium, phosphorus, albumin, or hemoglobin.\nDISCUSSION\nThe prevalence of constipation observed in our sample was 49.1% ( N=28), which falls within the range of prevalence rates reported in the literature.1-8 An earlier study, also conducted in Brazil's South region and investigating the same subject, found a constipation prevalence of 33.5% among patients on hemodialysis, also using the ROMA III criteria,5 supporting Ramos et al. (2015), who performed another study with patients on hemodialysis\nin Brazil, finding 32.8% of constipation among 290 participants. However, recent international data reveal higher prevalence rates, such as, for example, a study in Turkey that reported 71.7% constipation among participants (n=80), although it is important to take into consideration that diagnosis was based on the ROMA II criteria.\nIn our study, in addition to applying the ROMA III criteria, we also assessed patients' own perceptions of difficulty evacuating and the characteristics of their stools, using the Bristol Stool Form Scale. It is notable that a proportion of the patients who were classified as constipated by the ROMA criteria did not perceive themselves as constipated when asked if they had difficulty evacuating.\nStudies that employ patients' own perception of constipation generally report higher prevalence rates than studies that define constipation using the ROMA classification. , In contrast, in our study the prevalence of constipation according to the ROMA criteria was higher than according to patients' own perceptions of difficulty evacuating (49.1 vs. 36.8%), possibly because the patient's own perception of constipation was only measured using a single item on the questionnaire, although use of additional methods to assess bowel habits, made it possible, for example, to observe a higher frequency of gastrointestinal symptoms among constipated patients, although these differences did not attain statistical significance, perhaps because of insufficient sample size.\nThese discrepancies between the prevalence rates in different studies could therefore be the result of differences in personal perceptions of the problem, or the validity of the diagnostic criteria used. Additionally, use of questionnaires is dependent on the patient's ability to recall symptoms from months earlier. A recent study of 148 patients in Australia with CKD at different stages of the disease that assessed the correlation between patients' perceptions of constipation ad the ROMA III criteria and the Bristol scale concluded that no single method is sufficient to determine with precision whether a patient is or is not\nconstipated. According to the ROMA III criteria, just 12.3% of the sample were classified as constipated; 27.5% by the Bristol scale; and 46.3% according to patients' own perceptions. The authors therefore concluded that basing assessments on patients' own perceptions may be unreliable because constipation diagnosis in this population should use at least 2 sets of criteria, such as Roma III and the Bristol Scale.\nIn this study we did not investigate other types of treatment for end stage CKD, such as peritoneal dialysis, since only 6 patients at our dialysis center use this treatment method. However, it is of interest to note that this form of RRT appears to be associated with a lower frequency of constipation, compared with patients on hemodialysis. , , For example, Zhang et al.9 assessed 605 patients on RRT and found an extremely significant difference between the prevalence of constipation on hemodialysis (71.7%) and on peritoneal dialysis (14.2%).\nWith regard to factors associated with constipation, in contrast with many studies in the general population, where constipation is more prevalent among females, , , in our study there was no significant difference between men and women, suggesting that in the population on hemodialysis gender does not appear to be a determinant factor in presence or absence of this symptom. It is possible that other factors present in this population are more relevant than sex.\nThe association between use of phosphate binders, especially calcium carbonate, and constipation was not significant in our study, probably due to the small sample size. However, associations with calcium-based phosphate binders have been observed in clinical practice and described in other studies, , , , and use of these agents is reducing because of their side effects, which are not only related to gastrointestinal issues, but also to hyperkalemia.\nThere are few current studies on use of calcium carbonate in the international dialysis population,10,40 but calcium-free phosphate binders are widely studied and\n39 employed. In Brazil, calcium carbonate is still one of the most used chelating agents, probably because of its effectiveness in combination with the low cost,5,41 and this was also observed in our study.\nIn our study, there was a significant difference in the prevalence of constipation among participants who were taking or had previously taken laxatives and those who did not. However, it is difficult to answer whether use of these medications predisposes to constipation or whether constipated patients seek treatment for their problem with these drugs.\nFiber intake is a challenge for patients on hemodialysis. Anzuategui et al.5 concluded that mean fiber intake in their sample was 11 grams, which is a similar level to that observed in our study, where mean intake among constipated patients was 13.1g/day and 14.8g/day among those without constipation, while just four patients had an intake of more than 20g/day and only one attained the proposed target level of 25g/day, showing that achieving the recommended intake of 25g/day is a distant goal for this population. We should emphasize, however, that fiber intake was assessed using a food diary that was only completed by 45.6% of the sample. Recalls and diaries are subject to memory bias and to imprecise recordkeeping, whether caused by difficulties with completing and with remembering, whether because of reluctance to admit to the treating team that the diet prescribed is not being followed. In our sample, with a high prevalence of elderly patients, the role of memory bias may have been amplified.\nWe observed a positive and statistically significant association between physical inactivity and constipation in this study. In our sample, none of the five patients who reported being physically active were classified as constipated, whereas among physically inactive participants the prevalence was 53.8% (p = 0.05). Studies describe physical activity as inversely associated with constipation.42,43 Dukas et al.44 showed that physical activity at least twice a week was associated with a 35% lower risk of constipation, and daily physical activity\nwas associated with a 44% lower risk. In clinical practice, a high prevalence of inactivity among patients on hemodialysis is observed and this was confirmed in the present study. However, this practice should be encouraged among these patients, taking into consideration the limitations imposed by disease and comorbidities.\nSince constipation is unlikely to be associated with mortality, quality of life is the principal outcome to be evaluated in patients with this condition, especially when assessing the impact of therapeutic interventions. A study that is possibly one of the most complete studies of constipation in the general population investigated the impact of this symptom on the quality of life of 2,870 participants living in France, Germany, Italy, United Kingdom, South Korea, Brazil, and the United States.45 The results showed that quality of life, measured using the SF-36 instrument, was significantly worse in constipated than not constipated populations and that Brazilians were the nationality that most reported feeling affected by constipation, in terms of negative impact in social settings.\nWhile we did not investigate quality of life in depth in our study, we did include a question asking about whether gastrointestinal symptoms interfered with well-being. We found that constipated patients reported a greater frequency of negative impact on well-being from these symptoms than patients without constipation (77.3 vs. 22.7%, p 0.01). This association could be better investigated in future studies using validated instruments that are more fully adapted for this population.\nOur study has some potential limitations. Our sample probably represents a select population of patients with CKD who have access to the supplementary healthcare system (private or health insurance). While this is not the case of the majority of the Brazilian population, this is a growing group and one that has received little research attention. Second, the low rate of return of the food diaries means that the possibility of selection bias cannot be ruled out in relation to the nutritional information. The cross-sectional design is an inherent\nlimitation to analysis of cause and effect relationships between exposure variables (notably the behavioral variables such as physical activity level, use of chelating agents, use of laxatives, and fiber intake) and the outcome (constipation).\nWe conclude that constipation is a common symptom among patients on hemodialysis.\nUse of the ROMA III criteria to diagnose constipation enables diagnosis of a higher number of cases of than patients' own perception alone. The majority of patients in the sample use laxatives chronically, even though a considerable proportion of these patients did not consider themselves or were not classified as constipated according to the ROMA III criteria. Considering its high prevalence and its impact on wellbeing, whether patients have constipation should be routinely investigated in this population, to enable correct diagnosis and management.\nTABLES\nTable 1: Sample characteristics (n = 57)\nVariable\tn(%) or Mean\u00b1SD\nMale\t37 (64.9%)\nAge (Mean \u00b1 SD)\t70.8 \u00b1 11.5\nWhite skin\t47 (82.45%)\nPartnership status Mamed/Living together Years of education\t36 (63.2%)\n> 12\t31 (54.4%)\nInactivity Cause of CKD\t52 (91.22%)\nDM and/or SAH\t43 (75.4%)\nBMI (Kg/m2) Nutritional status\t25.3\u00b1 4.3\nMalnourished\t1 (1.8%)\nHealthy weight Overweight/Obesity\t32 (56.1%) 24 (42,1%)\nPre-Dialysis Biochemical Analyses Urea (mg/dL) Creatinine (mg/dL) Potassium (mEq/L) Phosphorus (mg/dL) Albumin (g/dL) Hemoglobin(g/dL)\t119.9 \u00b143.3 7.1 \u00b12.5 5.1\u00b10.7 4.7 \u00b11.4 3.7\u00b10.3 11.1\u00b11.5\n*CKD: Chonic Kidney Desease **DM: Diabetes Mellitus ***SAH: Hipertention Arterial Systemic\nTable 2: Prevalence of constipation and characteristics of stools (N = 57)\nN (%)\nConstipation*\n28 (49.1%)\nCharacteristics stools**\n1\n2\n3\n4\n5\n6\n7\nof\n\nSeparate hard lumps like nuts\t4 (7%)\nSausage-shaped, but\t11 (19.3%)\nlumpy\t\nLike a sausage, but with\t23 (40.4%)\ncracks on the surface\t\nLike a sausage or snake,\t11 (19.3%)\nsmooth and soft\t\nSoft blobs with clear-cut\t7 (12.3%)\nedges\t\nSoft pieces, but with\t1 (1.8%)\nragged edges\t\nWatery, no solid pieces\t0 (0%)\n*Constipation diagnosed according to ROMA III\n** Bristol Stool Form Scale\nTable 3. Factors associated with constipation in patients on hemodialysis (N = 57)\nVariables\t\tROMA III constipation N (%)\t\tP value*\n\t\tYes\tNo\t\nSex\tMale Female\t15 (40.5%) 13 (65%)\t22 (59.5%) 7 (35%)\t0.07\nAge (years)\t\t\t\t0.2\n\t<65\t10 (62.5%)\t6 (37.5%)\t\n\t>65\t18 (43.9%)\t23 (56.1%)\t\nYears at school\t\t\t\t0.5\n\t<8\t5 (62.5%)\t3 (37.5%)\t\n\t9-11\t7 (38.9%)\t11 (61.1%)\t\n\t>12\t16 (51.6%)\t15 (48.4%)\t\nDiabetes\t\t\t\t0.9\n\tYes\t15 (50%)\t15 (50%)\t\n\tNo\t13 (48.8%)\t14 (51.9%)\t\nPhysical activity\t\t\t\t0.05**\n\tYes\t0 (0%)\t5 (100%)\t\n\tNo\t28 (53.8%)\t24 (46.2%)\t\nUse of chelating agents\t\t\t\t0.11\n\tYes\t24 (54.5%)\t20 (45.5%)\t\n\tNo\t4 (30.8%)\t9 (69.2%)\t\nUse of laxatives\t\t\t\t0.001\n\tYes\t23 (67.6%)\t11 (32.4%)\t\n\tNo\t5 (21.7%)\t18 (78.3%)\t\nNutritional status\t\t\t\t0.2\n\tHealthy weight\t14 (43.8%)\t19 (56.2%)\t\n\tOverweight\t14 (58.3%)\t10 (41.7%)\t\n\t/Obesity\t\t\t\nChelating agent\t\t\t\t0.5\n\tCalcium Carbonate\t20 (57.1%)\t15 (42.9%)\t\n\tCalcium Carbonate\t2 (50%)\t2 (50%)\t\n\t+ Sevelamer\t\t\t\n\tSevelamer\t2 (33.3%)\t4 (66.7%)\t\n*Pearson's Chi- Square\t** Fischer's exact test\t\t\t\nTable 4- Self-reported prevalence of gastrointestinal symptoms (N=57)\nSymptoms\t\tROMA III constipation N (%)\t\tP value*\n\t\tYes\tNo\t\nStraining during defecations\tYes\t13 (61.9%)\t8 (38.1%)\t0.1\n\tNo\t15 (41.7%)\t21 (58.3%)\t\nAbdominal pains\tYes\t12 (60%)\t8 (40%)\t0.2\n\tNo\t16 (43.2%)\t21 (56.8%)\t\nAbdominal distension\tYes\t15 (57.7%)\t11 (42.3%)\t0.2\n\tNo\t13 (41.9%)\t18 (58.1%)\t\nNausea and Vomiting\tYes\t13 (56.5%)\t10 (43.5%)\t0.4\n\tNo\t15 (44.1%)\t19 (55.9%)\t\nFlatulence\tYes\t18 (60%)\t12 (40%)\t0.08\n\tNo\t10 (37%)\t17 (63%)\t\nSymptoms interference on well-being\tYes\t17 (77.3%)\t5 (22.7%)\t0.01\n\tNo\t11 (40.7%)\t16 (59.3%)\t\n* Pearson\u2019s Chi- Square\nTable 5: Nutritional composition of diet of patients on hemodialysis according to 2-day food diaries (N = 26)\n\tROMA III constipation (Mean \u00b1 SD)\t\tp value *\nNutrients\tYes\tNo\t\nCalories (Kcal)\t1630.6\u00b1341.4\t1346.1\u00b1289.3\t0.04\nProtein (g)\t82.9\u00b127.6\t59.5\u00b113.1\t0.02\nCarbohydrate (g)\t190.5\u00b143.3\t186.0\u00b149.4\t0.8\nLipids (g)\t54.5\u00b123.8\t43.7\u00b123.2\t0.3\nFiber (g)\t13.1\u00b15.8\t14.8\u00b15.9\t0.5\n*ANOVA\nARTICLE REFERENCES\n1.\tMurtagh FEM, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007; 14:82-99.\n2.\tDong R, Guo ZY, Ding JR, et al. Gastrointestinal symptoms: A comparison between patients undergoing peritoneal dialysis and hemodialysis. World J Gastroenterol. 2014; 20(32):11370-5\n3.\tGok EG, inci A, \u00c7oban M, et al. Functional bowel disorders and associated risk factors in hemodialysis patients in Turkey.Turk J Gastroenterol. 2017; 28(1):12-19.\n4.\tShirazian S, Radhakrishnan J. Gastrointestinal disorders and renal failure: exploring the connection. Nat Rev Nephrol. 2010; 6:480-492.\n5.\tAnzuategui, LSY, Holffman, K, Martins C, et al. A preval\u00eancia de constipa\u00e7\u00e3o em pacientes em di\u00e1lise cr\u00f4nica brasileira J Nephrol. 2008; 30: 137-143.\n6.\tCano AE, Neil AK, Kang JY, et al. Gastrointestinal symptoms in patients with end-Stage renal disease undergoing treatment by hemodialysis or peritoneal Dialysis. Am J Gastroenterol 2007; 102: 1990-7.\n7.\tYasuda G, Shibata K, Takizawa T, Ikeda Y, Tokita Y, Umemura S, et al. Prevalence of constipation in continuous ambulatory peritoneal dialysis patients and comparison with hemodialysis patients. Am J Kidney Dis. 2002; 39:1292-9\n8.\tRamos CI, Lim AFA, Grilli DG, et al. The Short -term effects of olive oil and flaxseed oil for the treatment of constipation in hemodialysis patients. J Renal Nutr 2015; 25(1):50-6\n9.\tZhang J, Huang C, Li Y, et al.Health-related quality of life in dialysis patients with constipation: a cross-sectional study. Patient Prefer Adherence. 2013; 7:589-94.\n10.\tPatel L, Bernard LM, Elder GJ.Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials..Clin J Am Soc Nephrol. 2016; 11(2):232-44.\n11.\tPoesen R, Meijers B, Evenepoel P. The colon: an overlooked site for therapeutics in dialysis patients. Semin Dial. 2013; 26: 323-332\n12.\tVitetta L, Gobe G. Uremia and chronic kidney disease: The role of the gut microflora and therapies with pro- and prebiotics. Mol. Nutr Food Res.2013; 57, 824-832.\n13.\tCigarran Guldris S, Gonzalez Parra E, Cases Amenos A. Gut microbiota in chronic kidney disease. Nefrologia. 2017; 37(1):9-19.\n1\t2\t3\n14.\tFujishiro M , Kushiyama A , Yamazaki H , et al. Gastrointestinal symptom prevalence depends on disease duration and gastrointestinal region in type 2 diabetes mellitus.World J Gastroenterol. 2017;23(36):6694-6704.\n15.\tRon Y, Wainstein J, Leibovitz A, Monastirsky N, Habot B, Avni Y, Segal R. The effect of acarbose on the colonic transit time of elderly long-term care patients with type 2 diabetes mellitus. J Gerontol A Biol Sci Med Sci. 2002;57(2):M111-4\n16.\tVinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553-1579\n17.\tWorld Gastroenterology Organization Practice Guidelines. Manejo dos sintomas comuns\nde doen\u00e7as gastrointestinais na comunidade Perspectiva mundial sobre azia, constipa\u00e7\u00e3o, distens\u00e3o e dor/ desconforto abdominal [Internet].[S.I.]: WHO,2013 .[Acessado em 06 ago 2017].\tDispon\u00edvel\tem\nhttp://www.worldgastroenterology.org/UserFiles/file/guidelines/common-gi-symptoms-portuguese-2013.pdf\n18.\tGilligan S, Raphael KL. Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes.Adv Chronic Kidney Dis. 2017;24(5):315-318.\n19.\tWald A, Scarpignato C , Mueller-Lissner S. et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther. 2008; 28: 917-930\n20.\tXing JH. Soffer EE. Adverse effects of laxatives. Dis Colon Rectum. 2001; 44: 12011209\n21.\tSutton D, Dumbleton S, Allaway C. Can increased dietary fibre reduce laxative requirement in peritoneal dialysis patients?J Ren Care. 2007; 33(4):174-8.\n22.\tWolff F, Brand\u00e3o ABM. Laxativos e Anti-Diarreicos. In: Fl\u00e1vio D. Fuchs; Lenita Wannmacher. (Org.). Farmacologia Cl\u00ednica - Fundamentos da Terap\u00eautica Racional. 4 ed. Rio de Janeiro, 2010, v. 1, p.5-10.\n23.\tFreitas JMM, Andrade de Lima PK, Falc\u00e3o KRW. Consumo de fibras e a preval\u00eancia de constipa\u00e7\u00e3o intestinal nos pacientes renais cr\u00f4nicos em hemodi\u00e1lise de uma cl\u00ednica nefrol\u00f3gica de Caruaru/PE. Nutri\u00e7\u00e3o Brasil 2016; 15(3):147-153\n24.\tDrossman DA. The functional gastrointestinal disorders and ROMA III progress. Gastroenterology.2006;130(5):1377-90\n25.\tLongstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480- 1491.\n26.\tRiegler G, Esposito I. Bristol scale stool form. A still valid help in medical practice and clinical research. Tech Coloproctol. 2001;5(3):163-4.\n27.\tMartinez AP, Azevedo GRD.The bristoL stool form scale: its translation to Portuguese, cultura adapatation and validation. Ver Lat -Am Enferm 2012; 20(3):583-89\n28.\tBRASIL. Minist\u00e9rio da Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Resolu\u00e7\u00e3o da Diretoria Colegiada -RDC N\u00b0 11, de 13 de mar. de 2014. Disp\u00f5e sobre os Requisitos de Boas Pr\u00e1ticas de Funcionamento para os Servi\u00e7os de Di\u00e1lise e d\u00e1 outras provid\u00eancias. Bras\u00edlia,DF, mar 2014.\n29.\tKidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3: 1-150.\n30.\tWorld Health Organization. Obesity: preventing and managing the global epidemic. Report of a World Health Organization Consultation. Geneva: World Health Organization, 2000. p. 256. WHO Obesity Technical Report Series, n. 284.\n31.\tUNIVERSIDADE ESTADUAL DE CAMPINAS - UNICAMP. Tabela brasileira de composi\u00e7\u00e3o de alimentos - TACO. 4. ed. rev. e ampl. Campinas: UNICAMP/NEPA, 2011.\n161 p. Dispon\u00edvel em:&lt;http://www.unicamp.br/nepa/taco/tabela.php?ativo=tabela>. Acesso em: 20 out. 2016.\n32.\tLee A, Lambert K, Byrne P, Lonergan M.Prevalence Of Constipation In Patients With Advanced Kidney Disease.J Ren Care. 2016;42(3):144-9.\n33.\tSetyapranata S1, Holt SG.The Gut in Older Patients on Peritoneal Dialysis.Perit Dial Int. 2015;35(6):650-4.\n34.\tCollete VL1, Ara\u00fajo CL, Madruga SW.Prevalence of intestinal constipation and associated factors: a population-based study in Pelotas, Rio Grande do Sul State, Brazil, 2007.Cad Saude Publica. 2010 Jul;26(7):1391-402. [Article in Portuguese]\n35.Schmulson Wasserman M, Francisconi C, Olden K, et al.The Latin-American Consensus on Chronic Constipation. Gastroenterol Hepatol. 2008 Feb;31(2):59-74. [Article in Spanish]\n36.\tBharucha AE, Pemberton JH, Locke GR 3rd. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144:218-238.\n37.\tNavaneethan SD1, Palmer SC, Vecchio M, et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.Cochrane Database Syst Rev. 2011 ;(2):CD006023.\n38.\tLiu Z, Su G, Guo X, Wu Y, et al. Dietary interventions for mineral and bone disorder in people with chronic kidney disease. Cochrane Database Syst Rev. 2015; (9):CD010350.\n39.\tWaheed AA1, Pedraza F, Lenz O, Isakova T. Phosphate control in end-stage renal disease: barriers and opportunities. Nephrol Dial Transplant. 2013; 28(12):2961-8.\n40.\tNerbass FB, Cuppari L, Avesani CM, et al. Decrease in Serum Phosphorus After Nutricional Intervention in Hyperphosphatemic Patients on Hemodialysis. J Bras Nefrol 2008;30(4):288-93 [Article in Portuguese]\n41.\tDe Schryver AM1, Keulemans YC, Peters HP,et al. Effects of regular physical activity on defecation pattern in middle-aged patients complaining of chronic constipation. Scand J Gastroenterol. 2005; 40(4):422-9.\n42.\tAnnells M1, Koch T.Constipation and the preached trio: diet, fluid intake, exercise. Int J Nurs Stud. 2003;40(8):843-52.\n43.\tDukas L1, Willett WC, Giovannucci EL. Association between physical activity, fiber intake, and other lifestyle variables and constipation in a study of women.Am J Gastroenterol. 2003;98(8):1790-6.\n44.\tWald A, Scarpignato C, Kamm MA, Mueller-Lissner S, Helfrich I, Schuijt C, et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther. 2007;26:227-36.\n8.\tCONCLUS\u00d5ES\n1)\tIdentificar a preval\u00eancia de constipa\u00e7\u00e3o na Unidade de Hemodi\u00e1lise do Hospital\nMoinhos de Vento em Porto Alegre, Brasil:\nIdentificamos uma preval\u00eancia de constipa\u00e7\u00e3o de 49,1% (N=28) na amostra investigada.\n2)\tIdentificar caracter\u00edsticas sociodemogr\u00e1ficas e comportamentais, comorbidades e medicamentos associados \u00e0 constipa\u00e7\u00e3o em pacientes em hemodi\u00e1lise:\nIdentificamos que a inatividade f\u00edsica, embora avaliada atrav\u00e9s de uma \u00fanica quest\u00e3o, esteverelacionada com a preval\u00eancia de constipa\u00e7\u00e3o nesta popula\u00e7\u00e3o, e que o sexo feminino demostrou uma tend\u00eancia de associa\u00e7\u00e3o, enquanto os demais itens pesquisados: diabetes, anos de estudo, uso de quelantes, tipo de quelantes de f\u00f3sforo, idade avan\u00e7ada e estado nutricional n\u00e3o mostraram associa\u00e7\u00e3o com a constipa\u00e7\u00e3o nesta popula\u00e7\u00e3o.\n3)\tIdentificar, atrav\u00e9s de recordat\u00f3rio alimentar, a associa\u00e7\u00e3o entre o consumo de fibras na dieta com a preval\u00eancia de constipa\u00e7\u00e3o:\nObservou-se que a m\u00e9dia da ingest\u00e3o de fibras nesta popula\u00e7\u00e3o \u00e9 pouco mais da metade da recomenda\u00e7\u00e3o usual de fibras para manejo da constipa\u00e7\u00e3o que \u00e9 de 25g/dia. A m\u00e9dia da ingest\u00e3o de fibras foi baixa, por\u00e9m n\u00e3o foi observada diferen\u00e7a significativa entre constipados e n\u00e3o constipados.\n9.\tPERSPECTIVAS\n1)\tEstudos de interven\u00e7\u00e3o para manejo da constipa\u00e7\u00e3o (incluindo ECR j\u00e1 aprovado no CEP)\n2)\tMelhor avalia\u00e7\u00e3o dos m\u00e9todos diagn\u00f3sticos para constipa\u00e7\u00e3o na popula\u00e7\u00e3o com DRC e em TRS.\n3)\tAvalia\u00e7\u00e3o do impacto da constipa\u00e7\u00e3o na qualidade de vida dos pacientes em HD e impacto dos tratamentos na qualidade de vida dos pacientes.\n10.\tCONSIDERA\u00c7\u00d5ES FINAIS\nA constipa\u00e7\u00e3o apresenta-se como um sintoma frequente na popula\u00e7\u00e3o em hemodi\u00e1lise. Sua etiologia \u00e9 multifatorial, e ainda requer investiga\u00e7\u00f5es mais profundas. Estudos nesta tem\u00e1tica t\u00eam grande import\u00e2ncia pr\u00e1tica, pois quando n\u00e3o tratada, a constipa\u00e7\u00e3o gera grande impacto no bem estar do paciente, al\u00e9m de poder elevar os custos para o sistema de sa\u00fade. At\u00e9 esse momento poucas s\u00e3o as alternativas para o manejo da constipa\u00e7\u00e3o nesta popula\u00e7\u00e3o, al\u00e9m de alternativas paliativas, como os laxativos. Tamb\u00e9m pouco se sabe sobre sua real interfer\u00eancia de formula\u00e7\u00f5es simbi\u00f3ticas e probi\u00f3ticas na atenua\u00e7\u00e3o deste sintoma em pacientes em di\u00e1lise, encorajando o prosseguimento desta linha de pesquisa para corroborar com um desfecho t\u00e3o importante como qualidade de vida, num tratamento, muitas vezes, de t\u00e3o longo prazo.\n11.\tREFER\u00caNCIAS BIBLIOGR\u00c1FICAS DISSERTA\u00c7\u00c3O\n1.\tBastos MG, Bregman R, Kirsztajn GM. Doen\u00e7a renal cr\u00f4nica: frequente e grave, mas tamb\u00e9m previs\u00edvel e trat\u00e1vel. Rev Assoc Med Bras. 2010;56(2):248-53.\n2.\tRiella MC. Princ\u00edpios de nefrologia e dist\u00farbios hidroeletrol\u00edticos. 5a.ed. Rio de Janeiro (RJ): Guanabara Koogan; 2010.1264 p. p.980-1019.\n3.\tTonelli M, Riella M. Chronic kidney disease and the aging population. Indian J Nephrol. 2014; 24(2): 71 -74.\n4.\tRom\u00e3o Jr JE. Doen\u00e7a renal cr\u00f4nica: defini\u00e7\u00e3o, epidemiologia e classifica\u00e7\u00e3o. J Bras Nefrol. 2004;26(3 Supl 1):1-3.\n5.\tDavison R, Sheerin NS. Prognosis and management of chronic kidney disease (CKD) at the end of life. Postgrad Med J. 2014 Feb;90(1060):98-105.\n6.\tWebster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet (London, England). 2017; 389(10075):1238-52.\n7.\tDaugidas JT, Blake P. Manual de Di\u00e1lise. Rio de Janeiro, RJ: Guanabara Koogan, 2007.\n8.\tLozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet,.2013; v. 380, p. 2095-128.\n9.\tVivekanand, JHA. et al. Chronic kidney disease: global dimensions and perspectives. Lancet. 2013. v. 382, p. 260-72.\n10.\tDavison R, Sheerin NS. Prognosis and management of chronic kidney disease (CKD) at the end of life. Postgrad Med J. 2014 Feb;90(1060):98-105.\n11.\tKolewaski CD, Mullally MC, Parsons TL, Paterson ML, Toffelmire EB, King-VanVlack CE.Quality of life and exercise rehabilitation in end stage renal disease. CANNT J 2005; 15:22-9.\n12.\tLee SY, Yang DH, Hwang E,et al. The Prevalence, Association, and Clinical Outcomes of Frailty in Maintenance Dialysis Patients.J Ren Nutr. 2017;27(2):106-112.\n13.\tCano AE, Neil AK, Kang JY, et al. Gastrointestinal symptoms in patients with end-Stage renal disease undergoing treatment by hemodialysis or peritoneal Dialysis. Am J Gastroenterol 2007; 102: 1990-7.\n14.\tFiderkiewicz B, Rydzewska-Rosolowska A, Mysliwiec M, et al. Factors associated with irritable bowel syndrome symptoms in hemodialysis patients. World J Gastroenterol. 2011; 17(15):1976-81.\n15.\tDong R, Guo ZY, Ding JR, et al. Gastrointestinal symptoms: A comparison between patients undergoing peritoneal dialysis and hemodialysis. World J Gastroenterol. 2014; 20(32):11370-5.\n16.\tMurtagh, FEM, Addington-Hall, J, Higginson, IJ. The prevalence of symptoms in endstage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007; 14:82-99.\n17.\tZhang J, Huang C, Li Y, et al.Health-related quality of life in dialysis patients with constipation: a cross-sectional study. Patient Prefer Adherence. 2013; 7:589-94.\n18.\tGok EG, inci A, \u00c7oban M, et al. Functional bowel disorders and associated risk factors in hemodialysis patients in Turkey.Turk J Gastroenterol. 2017; 28(1):12-19.\n19.Shirazian S, Radhakrishnan J. Gastrointestinal disorders and renal failure: exploring the connection. Nat Rev Nephrol. 2010; 6:480-492.\n20.\tAnzuategui, LSY, Holffman, K, Martins, C., Maciel, MARM, Anzuategui, RR, Riela, MC. A preval\u00eancia de constipa\u00e7\u00e3o em pacientes em di\u00e1lise cr\u00f4nica brasileira J Nephrol. 2008; 30: 137-143.\n21.\tYasuda G, Shibata K, Takizawa T, Ikeda Y, Tokita Y, Umemura S, et al. Prevalence of constipation in continuous ambulatory peritoneal dialysis patients and comparison with hemodialysis patients. Am J Kidney Dis. 2002; 39:1292-9.\n22.Strid, H., Simren, M., Johansson, A.C., Svedlund, J., Samuelsson, O., Bjornsson, E.S. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. Nephrol Dial Transplant. 2002; 17:1434-1439.\n23.\tSalamon K, Woods J, Paul E, Huggins C.Peritoneal dialysis patients have higher prevalence of gastrointestinal symptoms than hemodialysis patients.J Ren Nutr. 2013; 23(2):114-8.\n24.\tWald A, Scarpignato C, Kamm MA, Mueller-Lissner S, Helfrich I, Schuijt C, et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther. 2007; 26:227-36.\n25.\tSalmean YA, Zello GA, Dahl WJ. Foods with added fiber improve stool frequency in individuals with chronic kidney disease with no impact on appetite or overall quality of life.BMC Res Notes. 2013;6:510.\n26.\tDe Giorgio R, Ruggeri E, Stanghellini V, et al. Chronic constipation in the elderly: a primer for the gastroenterologist.BMC Gastroenterol. 2015;15:130.\n27.\tChang JY, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Risk factors for chronic constipation and a possible role of analgesics. Neurogastroenterol Motil. 2007; 19:905-11.\n28.\tWorld Gastroenterology Organisation Practice Guidelines. Manejo dos sintomas comuns\nde doen\u00e7as gastrointestinais na comunidade Perspectiva mundial sobre azia, consti\u00e7\u00e3o, distens\u00e3o e dor/ desconforto abdominal [Internet]. .[S.I.]: WHO,2013 .[Acessado em 06 ago 2017].\tDisponivel\tem\nhttp://www.worldgastroenterology.org/UserFiles/file/guidelines/common-gi-symptoms-portuguese-2013.pdf\n29.Palmer SC, Ruospo M, Campbell KL.et al. Nutrition and dietary intake and their association with mortality and hospitalisation in adults with chronic kidney disease treated with haemodialysis: protocol for DIET-HD, a prospective multinational cohort study. BMJ Open. 2015; 5(3).\n30.Suzuki D, Ichie T, Hayashi H, Sugiura Y, Sugiyama T. Gastrointestinal symptoms after the substitution of sevelamer hydrochloride with lanthanum carbonate in Japanese patients undergoing hemodialysis.Pharmazie. 2015; (8):522-6.\n31. Bernaud FSR, Rodrigues TC. Dietary fiber - Adequate intake and effects on metabolism healthArq Bras Endocrinol Metab. 2013;57/6. [Article in Portuguese]\n32.Sutton D, Ovington S, Engel B. A multi-centre, randomised trial to assess whether increased dietary fibre intake (using a fibre supplement or high-fibre foods) produces healthy bowel performance and reduces laxative requirement in free living patients on peritoneal dialysis.J Ren Care. 2014;40(3):157-63.\n33.\tHung SC, Lai YS, Kuo KL, Tarng DC. Volume overload and adverse outcomes in chronic kidney disease: clinical observational and animal studies.J Am Heart Assoc. 2015;4(5).\n34.\tLi YN, Shapiro B, Kim JC, Zhang M, et al. Association between quality of life and anxiety, depression, physical activity and physical performance in maintenance hemodialysis patients.Chronic Dis Transl Med. 2016;2(2):110-119.\n35.\tWald A, Scarpignato C, Mueller-Lissner S. et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther. 2008; 28: 917-930.\n36.\tXing JH, Soffer EE. Adverse effects of laxatives.Dis Colon Rectum. 2001;44(8):1201-9.\n37.\tCruz M, Andrade C, Urrutia M, Draibe S, Martins-Nogueira L, Sesso R. Quality of life in patients with chronic kidney disease. Clinics. 2011;66(6):991-5.\n38.\tKidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3: 1-150.\n39.\tBRASIL. Minist\u00e9rio da Sa\u00fade. Diretrizes Cl\u00ednicas para o cuidado ao paciente com Doen\u00e7a Renal Cr\u00f4nica - DRC, Bras\u00edlia, DF, 2014a. Dispon\u00edvel em: . Acesso em: 31 maio. 2017.\n40.\tParving HH. Hypertension and diabetes: the scope of the problem.Blood Press Suppl. 2001;2:25-31.\n41.\tSesso RC. Lopes AA, Thom\u00e9 FS, Lugon JR, Martins CT. Inqu\u00e9rito Brasileiro de Di\u00e1lise Cr\u00f4nica 2016. Bras Nefrol 2017;39(3):261-266.\n42.\tCassini AV, Malagutti W, Rodrigues FSM, Deus RB, Barnabe AS, Francisco L et al. Avalia\u00e7\u00e3o dos principais fatores etiol\u00f3gicos em indiv\u00edduos portadores de insufici\u00eancia renal cr\u00f4nica em hemodi\u00e1lise. ConScientiae Sa\u00fade. 2010;9(3):462-468.\n43.Sesso RC. Lopes AA, Thom\u00e9 FS, Lugon JR, Santos DR. Inqu\u00e9rito Brasileiro de Di\u00e1lise Cr\u00f4nica 2013 - An\u00e1lise das tend\u00eancias entre 2011 e 2013. J Bras Nefrol 2014;36(4):476-481.\n44.\tYamagata K, Yagisawa T, Nakai S, et al. Prevalence and incidence of chronic kidney disease stage G5 in Japan.Clin Exp Nephrol. 2015;1:54-64.\n45.\tERA-EDTA Registry: ERA-EDTA Registry Annual Report 2014. Academic Medical Center, Department of Medical Informatics, Amsterdam, the Netherlands, 2016.\n46.\tHallan SI, Stevens P. Screening for chronic kidney disease: which strategy.J Nephrol. 2010;23(2):147-55.\n47.\tLevey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811): 165-80.\n48.\tTonelli M, Riella M. Chronic kidney disease and the aging population. Indian J Nephrol. 2014; 24(2): 71-74.\n49.\tSaran R, Li Y, Robinson B, Ayanian J, et al. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2015;66 (1 Suppl 1).\n50.\tBello AK, Levin A, Tonelli M, et al. Assessment of Global Kidney Health Care Status.JAMA. 2017;317(18):1864-1881.\n51.\tRobinson BM, Akizawa T, Jager KJ, et al. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices.Lancet. 2016;388(10041):294-306.\n52.\tPalmer SC, Maggo JK, Campbell KL, et al. Dietary interventions for adults with chronic kidney disease.Cochrane Database Syst Rev. 2017;4:CD011998.\n53.\tSuki WN1, Moore LW1. Phosphorus Regulation in Chronic Kidney Disease.Methodist Debakey Cardiovasc J. 2016;12(4 Suppl):6-9.\n54.\tBreitsameter G1, Figueiredo AE, Kochhann DS. Calculation of Kt/V in haemodialysis: a comparison between the formulas.J Bras Nefrol. 2012;34(1):22-6. [Article in English, Portuguese]\n55.\tLee SY, Yang DH, Hwang E, et al. The Prevalence, Association, and Clinical Outcomes of Frailty in Maintenance Dialysis Patients.J Ren Nutr. 2017;27(2):106-112.\n56.\tChin H, Song Y, Lee S, Kim K, Na K. Moderately decrease renal function negatively affects the health - related quality of life among the elderly Koren population-based study. Nephrol Dial Transplant. 2008;23(9):2810-17.\n57.\tCond\u00e9 SAL; Fernandes N; Santos FR; Chouab A; Mota MMEP; Bastos, MG. Decl\u00ednio cognitivo, depress\u00e3o e qualidade de vida em pacientes de diferentes est\u00e1gios da doen\u00e7a renal cr\u00f4nica. J Bras Nefrol. 2010;32(3):242-248.\n58.\tWorld Gastroenterology Organisation Practice Guidelines. Constipa\u00e7\u00e3o: uma perspectiva mundial [Internet]. .[S.I.]: WHO,2010 .[Acessado em 06 ago 2017]. Disponivel em http://www.worldgastroenterology.org/UserFiles/file/guidelines/common-gi-symptoms-portuguese-2013.pdf\n59.\tRao SS. Constipation: evaluation and treatment of colonic and anorectal motility disorders.Gastrointest Endosc Clin N Am. 2009;19(1):117-39.\n60.\tCollete VL1, Ara\u00fajo CL, Madruga SW. Prevalence of intestinal constipation and associated factors: a population-based study in Pelotas, Rio Grande do Sul State, Brazil, 2007.Cad Saude Publica. 2010;26(7):1391-402. [Article in Portuguese]\n61.\tBove A, Bellini M, Battaglia E, et al. Consensus statement AIGO/ SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment). World J Gastroenterol. 2012; 18:4994-5013.\n62.\tGarrigues V, Galvez C, Ortiz V, Ponce M, Nos P, Ponce J. Prevalence of constipation: agreement among several criteria and evaluation of the diagnostic accuracy of qualifying symptoms and self-reported definition in a population-based survey in Spain. Am J Epidemiol. 2004; 159:520-526.\n63.\tLiu LW1. Chronic constipation: current treatment options.Can J Gastroenterol. 2011;25 Suppl B:22B-28B.\n64.Schmulson Wasserman M, Francisconi C, et al. The Latin-American Consensus on Chronic Constipation.Gastroenterol Hepatol. 2008;31(2):59-74. [Article in Spanish]\n65.\tBharucha AE, Pemberton JH, Locke GR 3rd. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013; 144:218-238\n66.\tSharma A, Rao S. Constipation: Pathophysiology and Current Therapeutic Approaches.Handb Exp Pharmacol. 2017;239:59-74.\n67.\tJohanson J, Kralstein J (2007) Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 25:599-606.\n68.\tDrossman DA. The functional gastrointestinal disorders and the Rome II process. Gut. 1999 Sep;45 Suppl 2:1-5.\n69.\tDrossman DA. The functional gastrointestinal disorders and ROMA III progress. Gastroenterology.2006 Apr;130(5):1377-90\n70Drossman DA, Hasler WL. Rome IV-functional GI disorders: Disorders of gutbrain interaction. Gastroenterology. 2016; 150:1257-61.\n71Juan J. Sebasti\u00e1n Domingo. Los nuevos criterios de Roma (IV) de los trastornos funcionales digestivos en la pr\u00e1ctica cl\u00ednica The new Rome criteria (IV) of functional digestive disorders in clinical practice. Med Clin 2017; 148:464-8.\n72.Riegler G, Esposito I. Bristol scale stool form. A still valid help in medical practice and clinical research. Tech Coloproctol. 2001;5(3):163-4.\n73.\tMacmillan AK, Merrie AE, Marshall RJ, Parry BR. Design and validation of a comprehensive fecal incontinence questionnaire. Dis Colon Rectum. 2008;51(10):1502-22.\n74.\tMartinez AP, Azevedo GRD.The bristoL stool form scale: its translation to Portuguese, cultura adapatation and validation. Ver Lat -Am Enferm 2012;20(3):583-89.\n75.\tLee A, Lambert K, Byrne P, Lonergan M. Prevalence of constipation in patients with advanced kidney disease. J Renal Care 2016; 42(3):144-49.\n76.\tYang J, Wang H-P, Zhou L, et al. Effect of dietary fiber on constipation: A meta-analysis. World J Gastroenterol 2012; 18(48): 7378-7383.\n77.\tAnderson JW, Baird P, Davis RH Jr, et al. Health benefits of dietary fiber.\nNutr Rev. 2009;67(4):188-205.\n78.\tHowlett JF, Betteridge VA, Champ M, Craig SAS, Meheust A, Jones JM. The definition of dietary fiber - discussions at the Ninth Vahouny Fiber Symposium: building scientific agreement. Food Nutr Res. 2010; 54:5750.\n79.\tTungland BC, Mayer D. Nondigestible oligo- and polysaccharides (dietary fiber): their physiology and role in human health and food. Comp Rev Food Sci Food Saf. 2002;1:73-92.\n80.\tDeVries JW. On defining dietary fibre. Proceedings of the Nutrition Society. 2003;46(3):112-29.\n81.\tPalit S, Lunniss PJ, Scott SM. The physiology of human defecation. Dig Dis Sci 2012; 57:1445-64.\n82.\tThomson AB, Drozdowski L, Iordache C, et al. Small bowel review: Normal physiology, part 2. Dig Dis Sci 2003; 48:1565-81.\n83.\tBrasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Departamento de Aten\u00e7\u00e3o B\u00e1sica. Guia alimentar para a popula\u00e7\u00e3o brasileira / Minist\u00e9rio da Sa\u00fade, Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade, Departamento de Aten\u00e7\u00e3o B\u00e1sica. - 2. ed., 1. reimpr. - Bras\u00edlia: Minist\u00e9rio da Sa\u00fade, 2014. 156 p.\n84.\tLembo A1, Camilleri M. Chronic constipation.N Engl J Med. 2003;349(14):1360-8.\n85.\tMiller LE , Ouwehand AC , Ibarra A. Effects of probiotic-containing products on stool frequency and intestinal transit in constipated adults: systematic review and meta-analysis of randomized controlled trials.Ann Gastroenterol. 2017;30(6):629-639.\n86.\tDimidi E, Christodoulides S, Fragkos KC,et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials.Am J Clin Nutr. 2014;100(4):1075-84.\n87.\tMachado W, Monteiro &amp; Capelari SM. Avalia\u00e7\u00e3o da efic\u00e1cia e do grau de ades\u00e3o ao uso prolongado de fibra diet\u00e9tica no tratamento da constipa\u00e7\u00e3o intestinal funcional. Rev. Nutr.2010;23(2):231-38.\n88.\tAnnells M, Koch T. Constipation and the preached trio: diet, fluid intake, exercise.Int J Nurs Stud. 2003;40(8):843-52.\n89.\tde Lira CA, Vancini RL, Ihara SS, da Silva AC, et al. Aerobic exercise affects C57BL/6 murine intestinal contractile function.Eur J Appl Physiol. 2008;103(2):215-23.\n90.\tDe Schryver AM, Keulemans YC, Peters HP, et al. Effects of regular physical activity on defecation pattern in middle-aged patients complaining of chronic constipation.Scand J Gastroenterol. 2005; 40(4):422-9.\n91.\tLi YN, Shapiro B, Kim JC, Zhang M, et al. Association between quality of life and anxiety, depression, physical activity and physicalperformance in maintenance hemodialysis patients.Chronic Dis Transl Med. 2016;2(2):110-119.\n92.\tSoares M. Medicamentos n\u00e3o Prescritos - Aconselhamento Farmac\u00eautico, 2a ed., Lisboa, vol. I e II, Publica\u00e7\u00f5es Farm\u00e1cia Portuguesa ANF, 2002.\n93.\tWolff FH, Brand\u00e3o ABM. Laxativos e Anti-Diarreicos. In: Fl\u00e1vio D. Fuchs; Lenita Wannmacher. (Org.). Farmacologia Cl\u00ednica - Fundamentos da Terap\u00eautica Racional. 4 ed. Rio de Janeiro, 2010, v. 1, p. 5-10.\n94.\tRamos CI, Lim AFA, Grilli DG, Cuppari L. The Short -term effects of olive oil and flaxseed oil for the treatment of constipation in hemodialysis patients. J Renal Nutr 2015;25(1):50-6.\n95.DeVries JW. On defining dietary fibre. Proceedings of the Nutrition Society. 2003;46(3):112-29.\n96.Sulaberidze G, Okujava M, Liluashvili K, Tughushi M, Abramashvili M. Impact of food enriched with dietary fiber on patients with constipationpredominant irritable bowel syndrome.Georgian Med News. 2017;(264):132-135.\n97.Tungland BC, Mayer D. Nondigestible oligo- and polysaccharides (dietary fiber): their physiology and role in human health and food. Comp Rev Food Sci Food Saf. 2002; 1:73-92.\n98.Sutton D1, Dumbleton S, Allaway C Can increased dietary fibre reduce laxative requirement in peritoneal dialysis patients?J Ren Care. 2007;33(4):174-8.\n99.\tNerbass FB, Cuppari L, Avesani CM, et al. Decrease in Serum Phosphorus After Nutritional Intervention in Hyperphosphatemic Patients on Hemodialysis. J Bras Nefrol 2008;30(4):288-93. [Article in Portuguese]\n100.\tLiu Z, Su G, Guo X, Wu Y, et al. Dietary interventions for mineral and bone disorder in people with chronic kidney disease. Cochrane Database Syst Rev. 2015; (9):CD010350.\n101.\tIhana-Sugiyama N, Nagata N, Yamamoto-Honda R, et AL. Constipation, hard stools, fecal urgency, and incomplete evacuation, but not diarrhea is associated with diabetes and its related factors.World J Gastroenterol. 2016;22(11):3252-60.\n102.\tVinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553-1579.\n103.\tFujishiro M, Kushiyama A, Yamazaki H, et al. Gastrointestinal symptom prevalence depends on disease duration and gastrointestinal region in type 2 diabetes mellitus.World J Gastroenterol. 2017;23(36):6694-6704.\n104.Saraiva MM . Transito do c\u00f3lon e diabetes. J Port Gastrenterol 2013;20(2):49-51.\n105.\tRon Y, Wainstein J, Leibovitz A, Monastirsky N, Habot B, Avni Y, Segal R. The effect of acarbose on the colonic transit time of elderly long-term care patients with type 2 diabetes mellitus. J Gerontol A Biol Sci Med Sci. 2002;57:M111-4.\n106.\tVitetta, L.; Gobe, G. Uremia and chronic kidney disease: The role of the gut microflora and therapies with pro- and prebiotics. Mol. Nutr. Food Res.2013, 57, 824-832.\n107.\tCigarran Guldris S, Gonzalez Parra E, Cases Amenos A. Gut microbiota in chronic kidney disease. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2017; 37(1):9-19.\n108.\tYamada E, Namiki Y, Takano Y, et al. Clinical factors associated with the symptoms of constipation in patients with diabetes mellitus: a multicenter study.J Gastroenterol Hepatol. 2017.\n109.\tPoesen R, Meijers B, Evenepoel P. The colon: an overlooked site for therapeutics in dialysis patients. Semin Dial 2013; 26: 323-332.\n110.\tGouroju S, Rao PVLNS, Bitla AR, et al. Role of Gut-derived Uremic Toxins on Oxidative Stress and Inflammation in Patients with Chronic Kidney Disease.Indian J Nephrol. 2017;27(5):359-364.\n111.\tRamezani A, Massy ZA, Meijers B, Evenepoel P, Vanholder R, Raj DS. Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2016; 67(3):483-98.\n112.\tMiller LE, Ouwehand AC, Ibarra A. Effects of probiotic-containing products on stool frequency and intestinal transit in constipated adults: systematic review and meta-analysis of randomized controlled trials.Ann Gastroenterol. 2017;30(6):629-639.\n113.\tVanholder R, Glorieux G. The intestine and the kidneys: a bad marriage can be hazardous. Clin Kidney J. 2015;8(2):168-79.\n114.\tRanganathan N, Ranganathan P, Friedman EA, et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther 2010; 27:634-647.\n115.\tNakabayashi I, Nakamura M, Kawakami K, et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant. 2011; 26:1094-1098.\n116.\tDi Cerbo A, Pezzuto F, Palmieri L, et al.Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update.Int Urol Nephrol 2013; 45: 1569-1576\n117.\tAlatriste PVM, Arronte RU, Espinosa COG, Cuevas MAE . Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr Hosp. 2014;29(3):582-590\n118.\tLiang-Min Xie, Yi-Yun Ge, Xin Huang, Yi-Qiong Zhang, Jun-Xuan Li . Effects of fermentable dietary fiber supplementation on oxidative and inflammatory status in hemodialysis patients Int J Clin Exp Med 2015;8(1):1363-1369.\n119.\tMafra D, Fouque D. Gut microbiota and inflammation in chronic kidney disease patients Clin Kidney J 2015.8 (3): 332-334.\n120.\tAron-Wisnewsky J, Clement K. The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nature reviews Nephrology. 2016; 12(3):169-81\n121.\tMazlyn MM, Nagarajah LH, Fatimah A, Norimah AK, Goh KL (2013) Effects of a probiotic fermented milk on functional constipation: a randomized, double-blind, placebo-controlled study. J Gastroenterol Hepatol 28:1141-1147\n122.\tKolida S, Gibson GR (2011) Synbiotics in health and disease. Annu Rev Food Sci Technol 2:373-393\n89\nANEXOS E AP\u00caNDICES\nAP\u00caNDICE I - TERMO DE CONSCENTIMENTO LIVRE E ESCLARECIDO\n4\nUFRGS\nUNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL\n\u201cEfeito da administra\u00e7\u00e3o oral de simbi\u00f3ticos na regula\u00e7\u00e3o intestinal e na qualidade de vida de pacientes em hemodi\u00e1lise: um ensaio cl\u00ednico randomizado\u201d (HEMOSIM)\nTERMO DE CONSENTIMENT O LIVRE E ESCLARECIDO\nA constipa\u00e7\u00e3o (pris\u00e3o de ventre, dificuldade em evacuar) \u00e9 um problema freq\u00fcentemente relatado em indiv\u00edduos que realizam hemodi\u00e1lise. Raramente, leva a problemas graves, por\u00e9m o desconforto provocado pode ser um fator que afeta negativamente \u00e0 qualidade de vida. Estudos tem mostrado que flora intestinal de quem tem Insufici\u00eancia Renal Cr\u00f4nica \u00e9 alterada em fun\u00e7\u00e3o da pr\u00f3pria doen\u00e7a e de medica\u00e7\u00f5es utilizada no seu tratamento, e que melhorar a flora intestinal atrav\u00e9s de suplementos contendo bact\u00e9rias ben\u00e9ficas e fibras (chamados de simbi\u00f3ticos) pode melhorar a qualidade de vida, os sintomas de pris\u00e3o de ventre e os exames laboratoriais de pacientes nesta condi\u00e7\u00e3o.\nNosso objetivo \u00e9 avaliar se esses suplementos (simbi\u00f3ticos) realmente ajudam a diminuir a constipa\u00e7\u00e3o, a melhorar a qualidade de vida e os exames laboratoriais de pacientes que fazem hemodi\u00e1lise. Para isso, ser\u00e1 desenvolvida pesquisa na qual, durante 1 m\u00eas, um grupo de pacientes receber\u00e1 uma dose di\u00e1ria de simbi\u00f3ticos, enquanto outro receber\u00e1 um envelope de igual aspecto contendo apenas uma subst\u00e2ncia sem a\u00e7\u00e3o sobre o organismo (placebo). A decis\u00e3o sobre que usar\u00e1 o simbi\u00f3tico e quem usar\u00e1 o placebo ser\u00e1 por sorteio, ou seja, at\u00e9 o final do estudo, nem voc\u00ea nem o pesquisador saber\u00e3o o que cada participante est\u00e1 usando.\n\u2022\tEsta pesquisa prev\u00ea o uso da medica\u00e7\u00e3o por um m\u00eas (30 dias no total).\n\u2022\tDurante esse per\u00edodo voc\u00ea dever\u00e1 evitar o uso de medica\u00e7\u00f5es laxativas sem orienta\u00e7\u00e3o de seu m\u00e9dico.\n\u2022\tVoc\u00ea ser\u00e1 acompanhado durante 30 dias, pelo nutricionista respons\u00e1vel pela pesquisa, durante sua sess\u00e3o de hemodi\u00e1lise, com 4 encontros semanais exclusivos. Neste mesmo momento ser\u00e3o entregues sem custo algum os saches que dever\u00e3o ser utilizados naquela semana.\n\u2022\tSer\u00e1 solicitado o preenchimento de um question\u00e1rio com informa\u00e7\u00e3o de dados pessoais e algumas informa\u00e7\u00f5es de seus h\u00e1bitos intestinais, e de ingest\u00e3o alimentar que ser\u00e1 reaplicado durante os acompanhamentos semanais at\u00e9 o final do estudo.\n\u2022\tNa primeira consulta tamb\u00e9m ser\u00e1 realizada medida de altura para avalia\u00e7\u00e3o do seu estado nutricional. Esta medida n\u00e3o \u00e9 invasiva e n\u00e3o causam riscos a sua sa\u00fade.\n\u2022\tSer\u00e3o coletados de seu prontu\u00e1rio os resultados dos exames que voc\u00ea j\u00e1 realiza rotineiramente na di\u00e1lise, n\u00e3o sendo necess\u00e1rias coletas extras de sangue.\n\u2022\tVoc\u00ea poder\u00e1 sentir, na primeira semana de acompanhamento, um pouco mais de flatul\u00eancias (Conhecidos como gazes). Esse sintoma tende a desaparecer ap\u00f3s a primeira semana de uso da formula\u00e7\u00e3o, sem causas problemas a sua sa\u00fade.\n\u2022\tEsses sach\u00eas tamb\u00e9m podem oferecer uma pequena quantidade de calorias, em torno de 45 kcal ao total por dia que provavelmente n\u00e3o influenciar\u00e3o no seu peso.\nSer\u00e3o fornecidos a voc\u00ea os dados das avalia\u00e7\u00f5es nutricionais realizada, bem como os resultados dos question\u00e1rios. Al\u00e9m disso, na presen\u00e7a de qualquer altera\u00e7\u00e3o ou desconforto seu m\u00e9dico assistente ser\u00e1 comunicado.\nEm qualquer momento voc\u00ea poder\u00e1 tirar d\u00favidas que possam existir sobre esta pesquisa, perguntando diretamente aos pesquisadores citados abaixo ou dirigindo-se ao Comit\u00ea de \u00c9tica em Pesquisa do Hospital Moinhos de Vento. Voc\u00ea ter\u00e1 total liberdade deixar a pesquisa a qualquer momento. Concordar ou n\u00e3o em participar deste estudo, n\u00e3o implicar\u00e1 nenhuma mudan\u00e7a no tratamento ou nos seus cuidados habituais, portanto, sinta-se com total liberdade para participar ou n\u00e3o.\nGarantimos sigilo quanto aos seus dados colhidos na pesquisa, assegurando-lhe absoluta privacidade. Al\u00e9m disso, voc\u00ea n\u00e3o ter\u00e1 nenhum preju\u00edzo financeiro por participar da pesquisa. Ressaltamos que voc\u00ea n\u00e3o receber\u00e1 ajuda financeira (dinheiro ou outros bens materiais) para participar da pesquisa. N\u00e3o s\u00e3o descritos riscos a sua sa\u00fade relacionados ou uso dos simbi\u00f3ticos conforme j\u00e1 foi dito, voc\u00ea poder\u00e1 ser observar um aumento de flatul\u00eancias (gazes) devido \u00e0 fermenta\u00e7\u00e3o intestinal, sintoma que normalmente n\u00e3o gera desconfortos maiores e costuma n\u00e3o persistir por mais de uma semana.\nEu, ______________________________________________, concordo em participar da referida\npesquisa ap\u00f3s ter sido informado (a) dos objetivos da pesquisa, de forma clara e detalhada. Recebi informa\u00e7\u00f5es e esclareci minhas d\u00favidas. Sei que em qualquer momento poderei solicitar novas informa\u00e7\u00f5es e modificar a minha decis\u00e3o se eu desejar. Fui informado de que todos os dados da pesquisa ser\u00e3o confidenciais, que n\u00e3o haver\u00e1 preju\u00edzo ao tratamento que vem sendo feito, e de que terei total liberdade de retirar meu consentimento de participa\u00e7\u00e3o na pesquisa a qualquer momento.\nCaso surjam d\u00favidas sobre o estudo, ficam a disposi\u00e7\u00e3o os pesquisadores respons\u00e1veis para esclarecimentos: Nut. Etielle Pereira Sonaglio (51-8222.22.34), Dr.Fernando Herz Wolff (519249.09.79) e Comit\u00ea de \u00c9tica em Pesquisa da Associa\u00e7\u00e3o Hospitalar Moinhos de Vento - sob coordena\u00e7\u00e3o Dr. S\u00e9rgio Amant\u00e9a, fone (51- 3314 3690) - para quest\u00f5es sobre a pesquisa e sobre os direitos dos pacientes envolvidos ou sobre problemas decorrentes da pesquisa.\n/ /\nAssinatura do paciente\tNome\tData / /\nAssinatura do pesquisador\tNome\tData\nEste formul\u00e1rio foi lido para\t\tem\t/\t/\n\tpor Etielle Pereira Sonaglio\t\nAP\u00caNDICE II - INSTRUMENTO DE COLETA DE DADOS\nUNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL - UFRGS\nFACULDADE DE MEDICINA Programa de P\u00f3s-Gradua\u00e7\u00e3o em Gastroenterologia\n1.\tNumero de identifica\u00e7\u00e3o:_____________\n2.\tNome do paciente :______________________________Iniciais_______________\n3.\tData da entrevista INICIAL: l_l______l / l_l_l /201 l\n4.\tData de nascimento: l_l____l / l_l_l /l__l_____l_I__I\n5.\tIdade: l_l_____l anos\n6.\tSexo: l__l 1. Masculino l__l 2. Feminino\n7.\tTempo que realiza hemodi\u00e1lise em anos?______________\n8.\t\u00c9 diab\u00e9tico? l_l 1. Sim l__l 2. N\u00e3o\n9.\tPatologia de base : l_l 1. DM l__l 2. HAS l____l 3. GLOMERONEFRITES l______l 4 . OUTROS l___l\n5. DESCONHECIDO\n10.\tQual \u00e9 sua cor ou ra\u00e7a? l_l 1. Branca l_l 2. N\u00e3o -Branca\n11.\tEscolaridade em anos de estudo:_______________\n12.\tQual seu estado conjugal?\nl__l 1. Solteiro(a)\tl____l 2. Casado (a) l___l 3. Vivendo como casado(a)\nl__l 4. Separado(a)\tl____l 5. Vi\u00favo\n13.\tRealiza atividade f\u00edsica regular: l_l 1. Sim l___l 2.N\u00e3o\n14.\tSe sim, qual atividade f\u00edsica realiza, e em qual frequ\u00eancia?______\n15.\t\u00c9 candidato a transplante renal? l__l 1. Sim l___l 2. N\u00e3o\n16. Voc\u00ea apresenta ou apresentou nos \u00faltimos meses algum destes sintomas gastrointestinais abaixo?\nDificuldade de evacuar\tl\tl 1. Sim\tl\tl 2. N\u00e3o\nDores abdominais\tl\tl 1. Sim\tl\tl 2. N\u00e3o\nDistens\u00e3o abdominal ( \u201c barriga inchada\u201d)\tl\t_l 1. Sim\tl\tl 2. N\u00e3o\nV\u00f4mitos e N\u00e1useas ( Enj\u00f4o)\tl\tl 1. Sim\tl\tl 2. N\u00e3o\nGases /Flatul\u00eancias\tl\t\tl 1. Sim\tl\tl 2. N\u00e3o\nDiarreia\tl\tl 1. Sim\tl\tl 2. N\u00e3o\n17. Esses sintomas interferem de maneira significativa no seu bem-estar?\nl__l 1. Sim l_______l 2. N\u00e3o\n18. Utiliza atualmente medicamentos laxantes ou produtos para evacuar ( Ex: Ch\u00e1s, caps\u00falas, fibras, probi\u00f3ticos) ? l_l 1. Sim l_____l 2. N\u00e3o\nSe sim, a cada quanto tempo ? E qual produto voc\u00ea utiliza?_________________________________\nJ\u00e1 utilizou algum produto em algum momento do seu tratamento? Se sim, qual e em qual dose?\n19. Utiliza atualmente quelantes de f\u00f3sforo? l_l 1. Sim l___l 2. N\u00e3o\nSe voc\u00ea respondeu SIM, qual a frequ\u00eancia e qual o quelante e em qual dose?______________________________________________________________\nEsta parte ser\u00e1 preenchida pelo pesquisador:\nAvalia\u00e7\u00e3o Antropom\u00e9trica\nMEDIDAS\nINCIAL\nFINAL\n_____________________________DATA COLETA:__________DATA DA COLETA: PESO SECO ALTURA\nIMC\nCLASSIFICACAO\nNUTRICIONAL\nAn\u00e1lises laboratoriais iniciais e finais_______\nINCIAL\nFINAL\n____________________________DATA COLETA:________DATA DA COLETA:\nUR\u00c9IA\nCREATININA\nPOT\u00c1SSIO\nF\u00d3SFORO\nALBUMINA\nHEMOGLOBINA\nACOMPANHAMENTOS:\nSEMANA 1\nDATA:\nSEMANA 2\nDATA:\nSEMANA 3\nDATA:\nSEMANA 4\nDATA:\nRESULTADO DE BRISTOL SINTOMAS DEVOLU\u00c7\u00c3O DOS SACH\u00caS VAZIOS UTILZADOS\nANEXO I - CRIT\u00c9RIOS PARA CONSTIPA\u00c7\u00c3O - ROMA III\nConstipa\u00e7\u00e3o funcional (ROMA III)\n** As quest\u00f5es foram adaptadas para melhor interpreta\u00e7\u00e3o e uniformiza\u00e7\u00e3o das perguntas pelos entrevistadores\nOs crit\u00e9rios diagn\u00f3sticos devem incluir:\n1.\tDois ou mais dos seguintes:\nA)\tEsfor\u00e7o evacuat\u00f3rio durante pelo menos 25% das defeca\u00e7\u00f5es;\n**Sr(a) faz muito for\u00e7a para evacuar em pelo menos C (1 em cada 4) das suas evacua\u00e7\u00f5es?\nl__l 1. Sim l___l 2. N\u00e3o\nB)\t. Fezes grumosas ou duras em pelo menos 25% das defeca\u00e7\u00f5es;\n**As suas fezes s\u00e3o em grumos, endurecidas, em pelo menos C (1 em cada 4) das suas evacua\u00e7\u00f5es?\nl__l 1. Sim l___l 2. N\u00e3o\nC)\tSensa\u00e7\u00e3o de evacua\u00e7\u00e3o incompleta em pelo menos 25% das defeca\u00e7\u00f5es;\n**Sr(a) tem a sensa\u00e7\u00e3o que n\u00e3o evacuou completamente, _falta sair alguma coisa, em pelo menos C (1 em cada 4) das suas evacua\u00e7\u00f5es?\nl__l 1. Sim l___l 2. N\u00e3o\nD)\t. Sensa\u00e7\u00e3o de obstru\u00e7\u00e3o/bloqueio anorretal das fezes em pelo menos 25% das defeca\u00e7\u00f5es;\n**Sr(a) tem a sensa\u00e7\u00e3o de querer evacuar, mas n\u00e3o conseguir em pelo menos C (1 em cada 4) das suas evacua\u00e7\u00f5es? Como se algo n\u00e3o permitisse a sa\u00edda das fezes?\nl__l 1. Sim l___l 2. N\u00e3o\nE)\t. Manobras manuais para facilitar pelo menos 25% das defeca\u00e7\u00f5es (por exemplo, evacua\u00e7\u00e3o com ajuda digital, apoio do assoalho p\u00e9lvico);\n**Sr(a) tem que ajudar com as m\u00e3os a sa\u00edda das fezes em pelo menos C (1 em cada 4) das suas evacua\u00e7\u00f5es?\nl__l 1. Sim l___l 2. N\u00e3o\nF)\t. Menos de tr\u00eas evacua\u00e7\u00f5es por semana.\n**Sr(a) evacua a cada quanto tempo?\nl__l 1. Sim l___l 2. N\u00e3o\n2.\tFezes moles est\u00e3o raramente presentes sem o uso de laxantes;\n**Sr(a) tem fezes amolecidas sem uso de laxantes?\nl__l 1. Sim l__l 2. N\u00e3o\n3.\tCrit\u00e9rios insuficientes para SII.\nCrit\u00e9rios preenchidos nos \u00faltimos 3 meses com in\u00edcio dos sintomas pelo menos 6 meses antes do diagn\u00f3stico.\n**Essas respostas s\u00e3o referentes a pelo menos 3 meses? Come\u00e7aram h\u00e1 uns 6 meses ao menos?\nl__l 1. Sim l____l 2. N\u00e3o\nANEXO II- ESCALA DE BRISTOL\nANEXO III - REGISTRO ALIMENTAR\nREGISTRO ALIMENTAR ( )DIA SEM DI\u00c1LISE ( )DIA COM DI\u00c1LISE\nNOME:\nN\u00daMERO:( DATA: /\t/\t)\nDesjejum\nDescrever todos os alimentos ingeridos na refei\u00e7\u00e3o como por exemplo: a\u00e7\u00facar, ado\u00e7ante, gel\u00e9ia, etc, especificando as quantidades de cada alimento.\nLanche da Manh\u00e3\nLanche da Tarde\nCeia"}]}}}